var title_f4_53_4944="Acute urticaria child PI";
var content_f4_53_4944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F51694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F51694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hives that have merged",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hives are sometimes so widespread that they start to merge together, covering a lot of skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, MD, Ludwig S, MD, Baskin MN, MD. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4944=[""].join("\n");
var outline_f4_53_4944=null;
var title_f4_53_4945="Candidal diaper dermatitis B";
var content_f4_53_4945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Candida diaper dermatitis in an infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chronic occlusion by wet diapers predisposes to infection, which initially begins in the perianal area with subsequent extension to the perineum and inguinal creases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Annette Wagner, Children's Memorial Hospital, Chicago, IL.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4945=[""].join("\n");
var outline_f4_53_4945=null;
var title_f4_53_4946="Patient information: Using a catheter to empty the bladder (The Basics)";
var content_f4_53_4946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86020\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"         Anatomy of the urinary tract",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/30/34273\">",
"          Putting in a catheter (Men)",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/32/28162\">",
"           Putting in a catheter (Women)",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/0/16386\">",
"         Patient information: Neurogenic bladder in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/53/27475\">",
"         Patient information: Paraplegia and quadriplegia (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Using a catheter to empty the bladder (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1833890533\">",
"      <span class=\"h1\">",
"       What is a catheter?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A catheter is a thin tube that goes inside the body. Some catheters are used to empty the bladder. These are called &ldquo;urinary catheters.&rdquo; They are placed in the &ldquo;urethra,&rdquo; the tube that carries urine from your bladder out of the body (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1833890580\">",
"      <span class=\"h1\">",
"       Why do I need a catheter to empty my bladder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might need to use a catheter to empty your bladder if you have a condition that keeps you from urinating the normal way. These conditions include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Spinal cord injury &ndash; The spinal cord is the bundle of nerves that runs down your back. If it is injured, you might not be able to control when you urinate.",
"       </li>",
"       <li>",
"        Neurogenic bladder &ndash; This condition causes problems with bladder control.",
"       </li>",
"       <li>",
"        Recovering from surgery &ndash; After some types of surgery, your body needs time to heal before you can urinate normally.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1833890595\">",
"      <span class=\"h1\">",
"       How do I put the catheter in?",
"      </span>",
"      &nbsp;&mdash;&nbsp;First, put all the things you will need to put the catheter in close by, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The catheter",
"       </li>",
"       <li>",
"        A container to catch the urine (or you can drain it into the toilet)",
"       </li>",
"       <li>",
"        For men, a gel that helps the catheter slide into the penis (called &ldquo;lubricant&rdquo;). Examples include K-Y&reg; jelly or Surgilube&reg;. Do not use Vaseline&reg;.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Here are the steps for a man to put in a catheter (",
"      <a class=\"graphic graphic_figure graphicRef85930 \" href=\"UTD.htm?33/30/34273\">",
"       figure 2",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wash your hands with soap and water",
"       </li>",
"       <li>",
"        Clean the tip of your penis with soap and water",
"       </li>",
"       <li>",
"        Put lubricant on the catheter",
"       </li>",
"       <li>",
"        Hold your penis straight out, away from your body",
"       </li>",
"       <li>",
"        Gently put the catheter into your urethra",
"       </li>",
"       <li>",
"        After the catheter has gone in the length of your penis, it will be harder to push in. Relax, breathe deeply, and push the catheter about 1 more inch.",
"       </li>",
"       <li>",
"        Urine will start to flow out of the catheter. Hold the catheter steady until the urine stops.",
"       </li>",
"       <li>",
"        Take the catheter out slowly to make sure all the urine comes out.",
"       </li>",
"       <li>",
"        Clean the catheter with soap and water and store it in a clean, dry place.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Here are the steps for a woman to put in a catheter (",
"      <a class=\"graphic graphic_figure graphicRef85929 \" href=\"UTD.htm?27/32/28162\">",
"       figure 3",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wash your hands with soap and water",
"       </li>",
"       <li>",
"        Stand with one foot on the toilet, or another position that you find comfortable",
"       </li>",
"       <li>",
"        Clean the area around your urethra with soap and water",
"       </li>",
"       <li>",
"        With one hand, spread your labia with your fingers. Find the opening to your urethra with the tip of your first finger.",
"       </li>",
"       <li>",
"        With the other hand, gently put the catheter into the urethra. (Most women find it easier to use the hand they write with for this step.)",
"       </li>",
"       <li>",
"        Guide the catheter up toward your belly button.",
"       </li>",
"       <li>",
"        After the catheter has gone into your body about 2 to 3 inches, urine will start to flow",
"       </li>",
"       <li>",
"        After the urine starts flowing, keep pushing the catheter 1 more inch. Hold it in place until the urine flow stops and the bladder is empty.",
"       </li>",
"       <li>",
"        Take the catheter out slowly to make sure all the urine comes out.",
"       </li>",
"       <li>",
"        Clean the catheter with soap and water and store it in a clean, dry place.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1833890629\">",
"      <span class=\"h1\">",
"       How often should I use the catheter to empty my bladder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people use it between 3 and 6 times a day. Your doctor can tell you when and how often to use the catheter.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1833890644\">",
"      <span class=\"h1\">",
"       How long will I need to use a catheter to empty my bladder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a spinal cord injury or other long-term problem with controlling your bladder, you will need to use it for the rest of your life. If you have a different problem, you might only need to use it until your bladder starts working normally again. Your doctor will tell you when you can stop using the catheter.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1833890661\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/53/27475?source=see_link\">",
"       Patient information: Paraplegia and quadriplegia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/0/16386?source=see_link\">",
"       Patient information: Neurogenic bladder in adults (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/53/4946?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86020 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-F0BCE44B44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4946=[""].join("\n");
var outline_f4_53_4946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833890533\">",
"      What is a catheter?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833890580\">",
"      Why do I need a catheter to empty my bladder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833890595\">",
"      How do I put the catheter in?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833890629\">",
"      How often should I use the catheter to empty my bladder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833890644\">",
"      How long will I need to use a catheter to empty my bladder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833890661\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86020\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"      Anatomy of the urinary tract",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/30/34273\">",
"       Putting in a catheter (Men)",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/32/28162\">",
"        Putting in a catheter (Women)",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/0/16386?source=related_link\">",
"      Patient information: Neurogenic bladder in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/53/27475?source=related_link\">",
"      Patient information: Paraplegia and quadriplegia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_53_4947="Mucus barrier disruption";
var content_f4_53_4947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disruption of the mucus barrier",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A prolific Serpulina biofilm adherent to the mucosa (green serpentine covering the mucosa), which creates access for other colonic bacteria (yellow for bacteroides and red fluorescence for Eubacterium rectale x400).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alexander Swidsinski, MD, and Vera Loening-Baucke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4947=[""].join("\n");
var outline_f4_53_4947=null;
var title_f4_53_4948="Sodium citrate and potassium citrate: Pediatric drug information";
var content_f4_53_4948=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium citrate and potassium citrate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22211?source=see_link\">",
"    see \"Sodium citrate and potassium citrate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/24/7556?source=see_link\">",
"    see \"Sodium citrate and potassium citrate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cytra-3;",
"     </li>",
"     <li>",
"      Tricitrates",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1006101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alkalinizing Agent, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12669151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     1 mL of oral solution contains 2 mEq of bicarbonate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dosing per mEq of bicarbonate: 2-3 mEq bicarbonate/kg/",
"     <b>",
"      day",
"     </b>",
"     (1-1.5 mL/kg/day) in 3-4 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1006112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22211?source=see_link\">",
"      see \"Sodium citrate and potassium citrate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     1 mL of oral solution contains 2 mEq of bicarbonate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Manufacturer&rsquo;s recommendation: Children: 5-15 mL (10-30 mEq bicarbonate) per dose after meals and at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alternative recommendation: Dosing per mEq of bicarbonate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children: 2&ndash;3 mEq bicarbonate/kg/",
"     <b>",
"      day",
"     </b>",
"     (1-1.5 mL/kg/",
"     <b>",
"      day",
"     </b>",
"     ) in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 15-30 mL (30-60 mEq bicarbonate) per dose after meals and at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     When using to alkalinize the urine, 10-15 mL doses given 4 times daily typically maintain urinary pH 6.5-7.4; doses 15-20 mL4 times daily usually maintain urinary pH at 7.0-7.6",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cytra-3: Citric acid 334 mg, sodium citrate 500 mg, and potassium citrate 550 mg per 5 mL (480 mL [DSC]) [equivalent to potassium 1 mEq, sodium 1 mEq, and bicarbonate 2 mEq per 1 mL; alcohol free, sugar free; contains sodium benzoate and propylene glycol; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tricitrates: Citric acid 334 mg, sodium citrate 500 mg, and potassium citrate 550 mg per 5 mL (480 mL) [equivalent to potassium 1 mEq, sodium 1 mEq, and bicarbonate 2 mEq per 1 mL; alcohol free; contains sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tricitrates: Citric acid 334 mg, sodium citrate 500 mg, and potassium citrate 550 mg per 5 mL (15 mL [DSC]; 30 mL [DSC]; 480 mL [DSC]) [equivalent to potassium 1 mEq, sodium 1 mEq, and bicarbonate 2 mEq per 1 mL; alcohol free, sugar free; contains sodiuim benzoate and propylene glycol; raspberry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10839524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should be diluted in water; may follow dose with additional water if necessary. Administer after meals and at bedtime to prevent osmotic saline laxative effect; shake well before use.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10839504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F), protect from excessive heating or freezing.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1006102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As long-term therapy to alkalinize the urine for control and/or dissolution of uric acid and cystine calculi of the urinary tract  [FDA approved in pediatric patients (age not specified) and adults]; treatment of chronic metabolic acidosis secondary to renal tubule disorders [FDA approved in pediatric patients (age not specified) and adults]; treatment of gout as adjuvant therapy with uricosuric drugs [FDA approved in pediatric patients (age not specified) and adults]. Has also been used for treatment of chronic metabolic acidosis due chronic diarrhea and some inborn errors of metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Polycitra may be confused with Bicitra",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F221779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Calcium levels, hyperkalemia, hypernatremia, metabolic alkalosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tetany",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10839486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sodium or potassium citrate or any component; severe renal impairment with oliguria or azotemia, Addison&rsquo;s disease (untreated) or severe myocardial damage",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10839488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in patients with cardiac disease, sodium- or fluid-retaining  conditions (eg, cardiac failure, hypertension, peripheral/pulmonary edema, toxemia of pregnancy), patients receiving other potassium-sparing drugs  or cardiac glycosides; patients on either a sodium- or potassium-restricted diet, use of single agent citrate formulation may be preferable; avoid use of aluminum-based antacids. Use with caution in patients with renal disease; may cause hyperkalemia or metabolic alkalosis. Undiluted solution can cause GI irritation; dilute with water prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10839487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some oral solutions contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use oral solution containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites. Some oral solutions contain propylene glycol; in neonates large amounts of propylene glycol (eg, &gt;3000 mg/day I.V.) have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use oral solutions containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not established (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11507149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution with toxemia of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10839525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Periodic serum (sodium, potassium, calcium, bicarbonate); urine pH",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10839505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     After absorption, citrate component metabolized via oxidation to bicarbonate which produces alkalinizing effect",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10839506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism:  &ge;95% via hepatic oxidation to bicarbonate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: &lt;5% unchanged in the urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1006117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/24/7556?source=see_link\">",
"      see \"Sodium citrate and potassium citrate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well before use; take after meals; dilute each dose with 1-3 oz of water and follow with additional water; palatability is improved by chilling solution. Notify physician if weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10839526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior to absorption, citrate ions effects are similar to chloride and therefore, does not affect gastrointestinal pH or disturb digestion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: 1 mL contains 1 mEq potassium, 1 mEq sodium, and 2 mEq of bicarbonate",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gal P and Reed M, &ldquo;Medications,&rdquo; Kliegman: Nelson Textbook of Pediatrics, 18th ed, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Inactive\" Ingredients in Pharmaceutical Products: Update (Subject Review). American Academy of Pediatrics Committee on Drugs,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/53/4948/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16047 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-7689716924-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4948=[""].join("\n");
var outline_f4_53_4948=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221767\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006101\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12669151\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006112\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221761\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221751\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10839524\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10839504\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006102\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914135\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221779\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10839486\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10839488\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10839487\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299053\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221757\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221758\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11507149\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10839525\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10839505\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10839506\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006117\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10839526\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16047\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16047|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22211?source=related_link\">",
"      Sodium citrate and potassium citrate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/24/7556?source=related_link\">",
"      Sodium citrate and potassium citrate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_53_4949="Hydralazine: Pediatric drug information";
var content_f4_53_4949=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydralazine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"    see \"Hydralazine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/40/8837?source=see_link\">",
"    see \"Hydralazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Hydralazine&reg;;",
"     </li>",
"     <li>",
"      Apresoline&reg;;",
"     </li>",
"     <li>",
"      Novo-Hylazin;",
"     </li>",
"     <li>",
"      Nu-Hydral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"      see \"Hydralazine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 0.75-1 mg/kg/day in 2-4 divided doses, not to exceed 25 mg/dose; increase over 3-4 weeks to maximum of 5 mg/kg/day in infants and 7.5 mg/kg/day in children, given in 2-4 divided doses; maximum daily dose: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: Initial: 0.1-0.2 mg/kg/dose (not to exceed 20 mg) every 4-6 hours as needed; up to 1.7-3.5 mg/kg/day divided in 4-6 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 10 mg 4 times/day, increase by 10-25 mg/dose every 2-5 days to maximum of 300 mg/day; usual dosage range for hypertension (JNC 7): 25-100 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: Hypertension: Initial: 10-20 mg/dose every 4-6 hours as needed, may increase to 40 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: Pre-eclampsia/eclampsia: 5 mg/dose then 5-10 mg every 20-30 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 8-16 hours in fast acetylators and every 12-24 hours in slow acetylators",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 20 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 10 mg, 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: Do not exceed rate of 0.2 mg/kg/minute; maximum concentration for I.V. use: 20 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F179506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Caspofungin, heparin, hydrocortisone sodium succinate, potassium chloride, verapamil, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aminophylline, ampicillin, furosemide, nesiritide, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Nitroglycerin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Digoxin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Changes color after contact with a metal filter; do not store intact ampuls in refrigerator",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of moderate to severe hypertension, CHF, hypertension secondary to pre-eclampsia/eclampsia, primary pulmonary hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F179508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       HydrALAZINE may be confused with hydrOXYzine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F179505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris, flushing, orthostatic hypotension, palpitations, paradoxical hypertension, peripheral edema, tachycardia, vascular collapse",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, depression, disorientation, dizziness, fever, headache, increased intracranial pressure (I.V.; in patient with pre-existing increased intracranial pressure), psychotic reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, nausea, paralytic ileus, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, erythrocyte count reduced, hemoglobin decreased, hemolytic anemia, leukopenia, thrombocytopenia (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps, peripheral neuritis, rheumatoid arthritis, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis, lacrimation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, drug-induced lupus-like syndrome (dose related; fever, arthralgia, splenomegaly, lymphadenopathy, asthenia, myalgia, malaise, pleuritic chest pain, edema, positive ANA, positive LE cells, maculopapular facial rash, positive direct Coombs' test, pericarditis, pericardial tamponade)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydralazine or any component; dissecting aortic aneurysm, mitral valve rheumatic heart disease, coronary artery disease",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Discontinue hydralazine in patients who develop SLE-like syndrome or positive ANA; use with caution in patients with severe renal disease or cerebral vascular accidents",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure closely with I.V. use; modify dosage in patients with severe renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F179495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F179431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1053202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid natural licorice (causes sodium and water retention and increases potassium loss); long-term use of hydralazine may cause pyridoxine deficiency resulting in numbness, tingling, and paresthesias; if symptoms develop, pyridoxine supplements may be needed",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F179446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal studies at 20-30 times the maximun daily human dose. Hydralazine crosses the placenta. Hydralazine is recommended for use in the management of hypertension associated with pre-eclampsia.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, ANA titer",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Direct vasodilation of arterioles (with little effect on veins) which results in decreased systemic resistance",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 20-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 5-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 2-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses placenta; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein-binding: 85% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Acetylated in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 30% to 50%; large first-pass effect orally",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, adults: 2-8 hours; half-life varies with genetically determined acetylation rates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 14% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/40/8837?source=see_link\">",
"      see \"Hydralazine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit alcohol; notify physician if flu-like symptoms occur",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Slow acetylators, patients with decreased renal function and patients receiving &gt;200 mg/day (chronically) are at higher risk for SLE. Titrate dosage to patient's response. Usually administered with diuretic and a beta-blocker to counteract hydralazine's side effects of sodium and water retention and reflex tachycardia.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F179442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     A flavored suspension (1.25 mg/mL) may be made with tablets. Dissolve seventy-five 50 mg hydralazine hydrochloride tablets in 250 mL of distilled water with 2250 g of Lycasin&reg; (75% w/w maltitol syrup vehicle). Add 3 g edetate disodium, then add 3 g sodium saccharin dissolved in 50 mL distilled water. Preserve solution with 30 mL of a solution containing methylparaben 10% (w/v) and propylparaben 2% (w/v) in propylene glycol. Flavor with 3 mL orange flavoring; add sufficient quantity of  distilled water to make 3 L. Adjust to pH 3.7 with glacial acetic acid. Label \"shake well\" and \"refrigerate\". Stable for 5 days at room temperature and at least 2 weeks refrigerated (preferred).",
"    </p>",
"    <div class=\"reference\">",
"     Alexander KS, Pudipeddi M, and Parker GA, \"Stability of Hydralazine Hydrochloride Syrup Compounded From Tablets,\"",
"     <i>",
"      Am J Hosp Pharm",
"     </i>",
"     , 1993, 50(4):683-6.",
"     <span class=\"pubmed-id\">",
"      8470684",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/53/4949/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13356 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-1B4384F6EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4949=[""].join("\n");
var outline_f4_53_4949=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179464\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053190\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053182\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179437\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179422\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053194\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179506\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053185\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053193\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179508\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179505\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053199\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053181\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053180\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179495\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179431\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053202\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179433\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179446\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053189\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053179\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053197\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053198\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053187\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053200\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179442\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13356\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13356|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=related_link\">",
"      Hydralazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/40/8837?source=related_link\">",
"      Hydralazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_53_4950="Betaxolol (ophthalmic): Drug information";
var content_f4_53_4950=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Betaxolol (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/14/21732?source=see_link\">",
"    see \"Betaxolol (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7995904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Betoptic S&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7995905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Betoptic&reg; S;",
"     </li>",
"     <li>",
"      Sandoz-Betaxolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7995909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7996020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Glaucoma:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solution: Instill 1-2 drops into affected eye(s) twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension (Betoptic&reg; S): Instill 1 drop into affected eye(s) twice daily.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7996019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Elevated intraocular pressure:",
"     </b>",
"     Ophthalmic suspension (Betoptic&reg; S): Instill 1 drop into affected eye(s) twice daily.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7996021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7996077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 0.5% (5 mL, 10 mL, 15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betoptic S&reg;: 0.25% (10 mL, 15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7995907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7996066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Shake suspension well before using. Tilt head back and instill in eye. Keep eye open and do not blink for 30 seconds. Apply gentle pressure to lacrimal sac for 1 minute. Wipe away excess from skin. Do not touch applicator to eye and do not contaminate tip of applicator.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7995932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Treatment of chronic open-angle glaucoma or ocular hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7995881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Betoptic&reg; S may be confused with Betagan&reg;, Timoptic&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7995937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Ocular: Short-term discomfort (&le;25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%: Alopecia, asthma, bradycardia, bronchial secretions thickened, bronchospasm, depression, dizziness, dyspnea, glossitis, heart block, heart failure, headache, hives, insomnia, lethargy, myasthenia gravis exacerbation, respiratory failure, smell/taste perversion, toxic epidermal necrolysis, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined: Ocular: Allergic reaction, anisocoria, blurred vision, choroidal detachment, corneal punctate keratitis, corneal punctate staining (with or without dendritic formations), corneal sensitivity decreased, corneal staining, crusty lashes, discharge, dry eyes, edema, erythema, foreign body sensation, inflammation, keratitis, ocular pain, photophobia, sensation of itching, tearing, visual acuity decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7995933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to betaxolol or any component of the formulation; sinus bradycardia; heart block greater than first-degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; uncompensated cardiac failure",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7995934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated heart failure and monitor for a worsening of the condition. Discontinue ophthalmic preparations with signs of cardiac failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Ophthalmic suspension contains benzalkonium chloride which may be absorbed by contact lenses; remove contact lens prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis. Should not be used alone in angle-closure glaucoma (has no effect on pupillary constriction). Choroidal detachment has been reported with aqueous suppressant therapy after filtration procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9770058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives.  Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8043201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10533824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; therefore, the manufacturer classifies Betaxolol (Ophthalmic) as pregnancy category C. When administered orally, betaxolol crosses the placenta, and can be detected in the amniotic fluid and umbilical cord blood. Refer to the Betaxolol (Systemic) monograph for details. The amount of betaxolol available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral doses; however, a minor effect on maternal heart rate and blood pressure may be observed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8043202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10533827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered orally, betaxolol is excreted into breast milk. Refer to the Betaxolol (Systemic) monograph for details. The amount of betaxolol available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral doses.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7996079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Betaxolol HCl Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (5 mL): $63.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Betoptic-S Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (10 mL): $198.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7996068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Axoptic (MY);",
"     </li>",
"     <li>",
"      Bertocil (PT);",
"     </li>",
"     <li>",
"      Betasel (AR);",
"     </li>",
"     <li>",
"      Betasel S (AR);",
"     </li>",
"     <li>",
"      Betaxa (BG);",
"     </li>",
"     <li>",
"      Betaxen (PK);",
"     </li>",
"     <li>",
"      Betaxol (VE);",
"     </li>",
"     <li>",
"      Betoptic (AE, AT, AU, BE, BF, BH, BJ, BR, CI, CN, CO, CY, CZ, DK, EG, ET, FR, GB, GH, GM, GN, GR, HN, IE, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PK, PT, PY, QA, RU, SA, SC, SD, SE, SK, SL, SN, SY, TN, TR, TW, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Betoptic S (AU, BG, BR, CH, CL, CN, CO, CR, CZ, EE, FI, GT, HK, IL, KP, MY, NI, NO, NZ, PA, PH, PL, PY, SE, SG, SV, TH, TW, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Betoptima (DE, ID);",
"     </li>",
"     <li>",
"      Betoquin (AU);",
"     </li>",
"     <li>",
"      Optibet (ID);",
"     </li>",
"     <li>",
"      Optipres (IN);",
"     </li>",
"     <li>",
"      Oxol (PH);",
"     </li>",
"     <li>",
"      Vistagan (PK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7996005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively blocks beta",
"     <sub>",
"      1",
"     </sub>",
"     -receptors, with little or no effect on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors; with ophthalmic use, reduces intraocular pressure by reducing the production of aqueous humor",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7996007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Intraocular pressure reduction: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &ge;12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapidly absorbed into the systemic circulation (concentrations ~",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      10",
"     </sub>",
"     to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      20",
"     </sub>",
"     of oral dosing) (Vainio-Jylh&auml;, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&gt;80%, as unchanged drug [15%] and inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Vainio-Jylh&auml; E, Vuori ML, Pyykk&ouml; K, et al, \"Plasma Concentration of Topically Applied Betaxolol in Elderly Glaucoma Patients,\"",
"      <i>",
"       J Ocul Pharmacol Ther",
"      </i>",
"      , 2001, 17(3):207-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/53/4950/abstract-text/11436941/pubmed\" id=\"11436941\" target=\"_blank\">",
"        11436941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8943 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-9B24B61484-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4950=[""].join("\n");
var outline_f4_53_4950=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995904\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995905\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995909\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996020\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996019\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996021\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996077\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995907\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996066\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995932\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995881\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995937\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995933\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995934\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298858\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770058\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8043201\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533824\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8043202\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533827\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996079\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996068\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962011\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996005\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996007\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8943\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8943|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/14/21732?source=related_link\">",
"      Betaxolol (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/24/37255?source=related_link\">",
"      Betaxolol (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/33/18965?source=related_link\">",
"      Betaxolol (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_53_4951="Spinal cord injury without radiographic abnormality (SCIWORA) in children";
var content_f4_53_4951=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spinal cord injury without radiographic abnormality (SCIWORA) in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/53/4951/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/53/4951/contributors\">",
"     Alison Chantal Caviness, MD, MPH, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/53/4951/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/53/4951/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/53/4951/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/53/4951/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/53/4951/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12191439\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord injury without radiographic abnormality (SCIWORA) refers to spinal injuries, typically located in the cervical region, in the absence of identifiable bony or ligamentous injury on complete, technically adequate plain radiographs or computed tomography. The majority of children with SCIWORA do have demonstrable injury of the spinal cord, spinal ligaments, or vertebral body end plate on magnetic resonance imaging (MRI). SCIWORA should be suspected in patients subjected to blunt trauma who report early (immediate) or transient symptoms of neurologic deficit or who have existing findings upon initial assessment. Treatment and prognosis are based upon neurologic presentation and MRI findings.",
"   </p>",
"   <p>",
"    This topic will review the clinical features and management of SCIWORA in children less than 18 years of age. The approach to ligamentous injury and SCIWORA in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\", section on 'Evaluation for ligamentous injury and SCIWORA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26108408\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord injury without radiographic abnormality (SCIWORA) was first defined in a series of children as objective signs of acute traumatic myelopathy in the absence of spinal column findings on plain radiographs, flexion-extension radiographs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    computed tomography (CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/1\">",
"     1",
"    </a>",
"    ]. In this original report, it was noted that patients had neurologic deficits or a history of transient paresthesias, numbness, or paralysis. Delayed onset of permanent paralysis, up to four days after injury, occurred in approximately half of patients.",
"   </p>",
"   <p>",
"    However, since the advent of magnetic resonance imaging (MRI) approximately two-thirds of cases described as SCIWORA in the literature actually have demonstrable injury to the spinal cord, soft tissue components of the spinal column (ligaments, capsules, or muscles), or vertebral body endplate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. With the increased availability of MRI, the diagnosis of &ldquo;real&rdquo; SCIWORA or spinal cord injury without",
"    <strong>",
"     neuroimaging",
"    </strong>",
"    abnormality is less common. However, the term SCIWORA is still commonly used to describe patients with neurologic findings suggestive of spinal cord injury with normal anatomic alignment and no bony abnormalities seen on plain film",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CT. Nonetheless, it is important to remember that patients with blunt trauma who have a history of transient neurologic symptoms that have resolved by the time of initial evaluation may have a significant injury to the spinal cord",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spinal column despite a normal physical examination and normal spine radiographs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CT.",
"   </p>",
"   <p>",
"    SCIWORA should not be confused with cervical &ldquo;burners&rdquo; or &ldquo;stingers&rdquo;, which refer to peripheral brachial plexus injuries, typically at the C5-C6 level resulting from trauma to the neck and shoulder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23689?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of cervical spinal cord and cervical peripheral nerve injuries in the young athlete\", section on 'Cervical burners'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7632003\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cervical spine is the most mobile portion of the spinal column and is most prone to traumatic injury. The thoracolumbar spine is partially braced by the rib cage and is less commonly deformed without fracture.",
"   </p>",
"   <p>",
"    Relative to adults, children have several distinct anatomic features that predispose them to hypermobility of the spinal column in the absence of apparent bony injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants, the ratio of head size and weight to the rest of the body is large, and the neck musculature is weak and limited in its ability to prevent hypermobility of the cervical spine.",
"     </li>",
"     <li>",
"      The spinal ligaments and capsules are elastic, allowing them to undergo significant stretching without tearing.",
"     </li>",
"     <li>",
"      The intervertebral disc and annulus have a high water content that allows for longitudinal expansion without rupture during spinal column distraction (as much as 2 inches [5 cm] in the neonate).",
"     </li>",
"     <li>",
"      The vertebral body facet joints are oriented horizontally and are shallow which permits significant bony motion during flexion, extension, or rotary neck movements.",
"     </li>",
"     <li>",
"      Anterior wedging of the vertebral bodies in infants and young children allows for increased forward bony movement.",
"     </li>",
"     <li>",
"      Children lack uncinate processes until approximately 10 years of age and thus, have less restriction of lateral and rotary spinal column movements.",
"     </li>",
"     <li>",
"      The growth zone of the vertebral body endplate is brittle and readily splits from the centrum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These anatomic features are most pronounced in infants and children under eight years of age and predispose them to upper cervical spinal cord injuries (cervical spine segments 1-3) after blunt trauma. Older children and adolescents are more likely to have lower cervical spinal cord injuries (cervical spine nerve segments 4-8). Full maturation of the cervical spine is not typically achieved until about 16 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H991129\">",
"    <span class=\"h2\">",
"     Mechanism of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four mechanisms of injury have been described for SCIWORA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperextension &ndash; With hyperextension of the cervical spine, the posterior interlaminar ligaments impinge upon the spinal canal causing up to 50 percent narrowing of the canal diameter. At the same time, spinal cord shortening leads to thickening in the cervical region [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/4\">",
"       4",
"      </a>",
"      ]. Further extension leads to bony displacement that, especially in the infant or young child, may be transient and followed by the spinal column springing back into normal bony position.",
"     </li>",
"     <li>",
"      Hyperflexion &ndash; The mechanism of spinal cord impingement following hyperflexion is similar to that of hyperextension. The anterior interlaminar ligaments impinge upon the cervical spinal canal causing narrowing at a point where spinal cord thickening occurs. Further flexion leads to transient bony displacement with further injury to the spinal cord.",
"     </li>",
"     <li>",
"      Distraction &ndash; Longitudinal distraction is most commonly seen in infants and children under five years of age. In these patients, the spinal column can be stretched well beyond the tolerance of the spinal cord without subsequent radiographic bony damage [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/5\">",
"       5",
"      </a>",
"      ]. Distraction with quadriplegia has occurred in neonates after breech extraction [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/6\">",
"       6",
"      </a>",
"      ], in young children restrained only by lap belts who are thrown forward during a front end motor vehicle collision, and in other rapid",
"      <span class=\"nowrap\">",
"       acceleration/deceleration",
"      </span>",
"      events.",
"     </li>",
"     <li>",
"      Spinal cord infarction &ndash; Vertebral artery occlusion with ischemia of the upper cervical spinal cord is seen in neonates as a result of failure of the atlanto-occipital articulation during delivery. Delayed thoracic spinal cord infarction in a five year old child who suffered high-energy thoracoabdominal trauma with retroperitoneal injury and hypotension has also been described [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26107899\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord injury without radiographic abnormality (SCIWORA) is a rare injury that is more likely to occur in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2,8-10\">",
"     2,8-10",
"    </a>",
"    ]. However, SCIWORA has been described in victims of all ages after blunt trauma. Most cases of SCIWORA occur in the cervical spine in both children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. Thoracic SCIWORA has also been described, but is less common than in the cervical region due to the splinting reinforcement provided by the rib cage and is primarily associated with extreme traumatic forces (eg, high-speed motor vehicle collisions). SCIWORA has been reported in the lumbar region in school-aged children and adolescents, but is very unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\", section on 'Evaluation for ligamentous injury and SCIWORA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCIWORA occurs with greater severity in children younger than eight years of age. Depending upon the study population, reported incidence has ranged from 4.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/12\">",
"     12",
"    </a>",
"    ] to approximately 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2\">",
"     2",
"    </a>",
"    ] in children with spinal injuries, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational study of over 95,000 children less than three years of age from the United States National Trauma Data Bank, SCIWORA occurred in 182 children (0.2 percent) and in 12 percent of all young children with cervical spine injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another review of data from the UK Trauma and Audit &amp; Research Network Database, which included nearly 20,000 pediatric trauma victims, SCIWORA occurred in 30 children (0.15 percent) and in 4.5 percent of all spine injured children [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one review of 103 children with cervical spine injury who were treated at a Level 1 pediatric trauma center, SCIWORA occurred in 39 children (38 percent) and in 21 of 28 (75 percent) of the children who had sports-related injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Among 21 studies of pediatric spinal cord injuries between 1923 and 1998, 237 cases of SCIWORA were described among a total of 937 patients (25 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SCIWORA in young children under eight years of age is most commonly caused by motor vehicle collisions, falls, and child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2\">",
"     2",
"    </a>",
"    ]. In older children, motor vehicle collisions and sports, especially gymnastics, diving, horseback riding, American football, and wrestling, predominate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26107906\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCIWORA may present as definite evidence of spinal cord injury on physical examination as manifested by abnormal vital signs (eg, apnea or bradycardia with hypotension [spinal shock]), neck or back pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurologic deficits (eg, paresthesias, paralysis, or loss of pain sensation) without evidence of bony abnormality on plain radiographs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    computed tomography of the spine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\", section on 'History'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, transient neurologic symptoms (eg, paresthesias, weakness) by history or resolving during emergency evaluation may be the only indication that the cervical or thoracic spinal cord has been injured [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. Approximately one-quarter of affected children may experience delayed onset of neurologic signs minutes to days after injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/14-16\">",
"     14-16",
"    </a>",
"    ], which can range from complete paralysis to partial neurologic deficits. The latent period may range from 30 minutes to four days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/1,15,16\">",
"     1,15,16",
"    </a>",
"    ], making prompt diagnosis difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, it is critical to have a high index of suspicion and to ask specifically about transient symptoms in any verbal child whose mechanism of injury is consistent with cervical or thoracic spine injury (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\", section on 'History'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26107920\">",
"    <span class=\"h1\">",
"     RADIOLOGIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with suspected spine or spinal cord injury should undergo plain radiographs of the cervical spine and any other portion of the spine with evidence of injury and computed tomography of the cervical spine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other region based on physical examination and plain radiographs. Magnetic resonance imaging (MRI) should be performed in children who are suspected of having spinal cord injury, but have normal plain radiographs (three view cervical spine or two view thoracic spine), computed tomography, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/18-21\">",
"     18-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 12 children with suspected traumatic spinal cord injury underwent examination with plain radiographs, CT, and MR imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/20\">",
"       20",
"      </a>",
"      ]. Six patients with normal radiographs and CT examinations had abnormal MRI studies revealing cord contusion, ligamentous injury, disc herniation, and epidural hematoma. Surgically correctable causes of spinal cord compression that were demonstrated by MRI in this study included disc herniation, epidural hematoma, and retropulsed fracture fragments.",
"     </li>",
"     <li>",
"      In another case series, abnormalities were found on 9 of 60 MRI studies performed in children with a final discharge diagnosis of SCIWORA [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/11\">",
"       11",
"      </a>",
"      ]. Abnormalities included spinal cord edema, hemorrhage, or infarction; increased spinal cord signal; and epidural hematoma.",
"     </li>",
"     <li>",
"      A series of nine children with SCIWORA under eight years of age, who all underwent MRI, found abnormalities in six (two spinal cord transections, three spinal cord contusions with hematomyelia, one spinal cord edema) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A literature review found that 163 of 268 patients (61 percent) with a clinical diagnosis of SCIWORA had spinal cord abnormalities or disc herniation on MRI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, MRI of children with SCIWORA frequently demonstrates injury to the spinal cord, including lesions requiring operative intervention (eg, epidural hematoma, ligamentous disruption).",
"   </p>",
"   <p>",
"    Spinal cord appearance on MR imaging also correlates with prognosis as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence of signal change within the spinal cord is associated with excellent prognosis. In one series, full neurologic recovery was seen in all 51 patients with a normal MRI, including six children with significant motor impairment at presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/11\">",
"       11",
"      </a>",
"      ]. In another series, full recovery at six months was seen in 23 patients with normal MRI; 21 of these patients had mild deficits at presentation, and two patients had a physical examination suggesting a complete spinal cord disruption [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2\">",
"       2",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Signal change consistent with edema or microhemorrhages is associated with improvement in neurologic function over time in some patients. In one review, two of five patients with &ldquo;minor&rdquo; hemorrhage on initial MRI improved to a mild neurologic deficit at six months while two of nine patients with spinal cord edema fully recovered, and seven had a mild deficit [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hematomyelia (hemorrhage into the spinal cord) and cord disruption are associated with severe, permanent neurologic injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2,11,19,23\">",
"       2,11,19,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26107927\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute management priorities in children with spinal cord injury without radiographic abnormality (SCIWORA) consist of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance of spinal immobilization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"       \"Pediatric cervical spine immobilization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Emergent support of airway, breathing, and circulation while treating other life-threatening injuries. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"       \"Trauma management: Approach to the unstable child\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Emergent consultation with a neurosurgeon with pediatric expertise. In some patients who have instability of the spinal column, emergent involvement of a pediatric orthopedist is also indicated.",
"     </li>",
"     <li>",
"      Definitive therapy should be based on the MRI findings and provided in consultation with a neurosurgeon with pediatric expertise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (eg, 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    initial loading dose over one hour followed by 5.4",
"    <span class=\"nowrap\">",
"     mg/kg/hour",
"    </span>",
"    for 23 to 48 hours) within the first three to eight hours after injury in those patients with an abnormal neurologic examination is controversial and is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link&amp;anchor=H21#H21\">",
"     \"Acute traumatic spinal cord injury\", section on 'Glucocorticoids'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990821\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with spinal cord injury without radiographic abnormality (SCIWORA) warrant hospital admission. Individual patients who meet all of the following criteria may be discharged from the emergency department in a padded hard cervical collar (eg, Miami J&reg; cervical collar):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of transient cervical neurologic symptoms that have fully resolved",
"     </li>",
"     <li>",
"      A normal detailed neurologic examination",
"     </li>",
"     <li>",
"      Normal plain radiographs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      computed tomography and a normal MRI",
"     </li>",
"     <li>",
"      No other serious injuries",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The parent and when applicable, the patient must fully understand the need for restriction of any activity (eg, sports, aggressive play, bicycle riding) that might lead to reinjury. Neurosurgical follow up within one to two weeks must be assured.",
"   </p>",
"   <p>",
"    Close follow-up of neurologic function by a neurosurgeon is necessary in all children with SCIWORA. Ongoing treatment in patients without operative lesions consists of prolonged external immobilization to permit healing of the presumed ligamentous injury and to prevent exacerbation of the myelopathy (eg, Guilford brace for cervical SCIWORA, thoracolumbar orthosis for thoracolumbar SCIWORA) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of bracing in children with SCIWORA is debated, and recommendations vary from no bracing in patients with transient symptoms and an initial normal MRI to a Guilford brace or thoracolumbar prosthesis for three months in patients with persistent deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2,11,24\">",
"     2,11,24",
"    </a>",
"    ]. Evidence supporting bracing and restriction of activities for three months derives from one case of recurrent injury with permanent neurologic deficit at 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2\">",
"     2",
"    </a>",
"    ] and a metaanalysis of cases of SCIWORA which found that recurrent injury was significantly more common in patients braced for 8 weeks versus 12 weeks (17 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/24\">",
"     24",
"    </a>",
"    ]. In contrast, a single hospital series of 189 children with SCIWORA reported 21 cases of recurrent SCIWORA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/11\">",
"     11",
"    </a>",
"    ]. The 85 patients treated with more rigid bracing had recurrent SCIWORA more frequently than did the 97 patients treated with a soft collar or no bracing (15 versus 7 percent, OR 2.3; 95% CI 0.9-6.0). All patients with recurrent SCIWORA had full neurologic recovery.",
"   </p>",
"   <p>",
"    One rational approach is to vary the duration of bracing depending on the presence of neurologic deficits, findings on MRI, and results of nerve conduction studies as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4951/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent neurologic deficit, positive MRI, or when performed, abnormal somatosensory evoked potentials &ndash; rigid brace for three months",
"     </li>",
"     <li>",
"      Transient resolved neurologic deficit or symptoms only and normal MRI or somatosensory evoked potentials &ndash; padded hard collar (eg, Miami J&reg; or Aspen Collar&reg;) for one to two weeks and reevaluation by a neurosurgeon",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26108436\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term spinal cord injury without radiographic abnormality (SCIWORA) is commonly used to describe patients with neurologic findings suggestive of spinal cord injury with normal anatomic alignment and no bony abnormalities seen on plain film",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      computed tomography of the spine. However, since the advent of magnetic resonance imaging (MRI), approximately two-thirds of children with SCIWORA actually have demonstrable injury to the spinal cord, soft tissue components of the spinal column (ligaments, capsules, or muscles), or vertebral body endplate. (See",
"      <a class=\"local\" href=\"#H26108408\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relative to adults, children have several distinct anatomic features that predispose them to hypermobility of the spinal column in the absence of apparent bony injury. (See",
"      <a class=\"local\" href=\"#H7632003\">",
"       'Pertinent anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SCIWORA typically involves the cervical spine and occurs with greater severity in children younger than eight years of age. Motor vehicle collisions, falls, and sports account for most instance of SCIWORA in children. (See",
"      <a class=\"local\" href=\"#H26107899\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SCIWORA may present as definite evidence of spinal cord injury on physical examination or subtle transient neurologic symptoms (eg, paresthesias, weakness). Approximately one-quarter of affected children may experience delayed onset of neurologic signs minutes to days after injury, which can range from complete paralysis to partial neurologic deficits. (See",
"      <a class=\"local\" href=\"#H26107906\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) should be performed in children who are suspected of having spinal cord injury, but have normal plain radiographs (three views)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      computed tomography of the cervical spine. (See",
"      <a class=\"local\" href=\"#H26107920\">",
"       'Radiologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute management priorities in children with spinal cord injury without radiographic abnormality (SCIWORA) consist of (see",
"      <a class=\"local\" href=\"#H26107927\">",
"       'Initial Management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Maintenance of spinal immobilization (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"       \"Pediatric cervical spine immobilization\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Emergent support of airway, breathing, and circulation while treating other life-threatening injuries (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"       \"Trauma management: Approach to the unstable child\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Emergent consultation with a neurosurgeon with pediatric expertise in patients needing spinal cord decompression or other neurosurgical intervention (eg, child with spinal epidural hematoma).",
"     </li>",
"     <li>",
"      Emergent consultation with a neurosurgeon",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      orthopedist with pediatric expertise in patients with spinal column instability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (eg, 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      initial loading dose over one hour followed by 5.4",
"      <span class=\"nowrap\">",
"       mg/kg/hour",
"      </span>",
"      for 23 to 48 hours) within the first three to eight hours after injury in those patients with an abnormal neurologic examination is controversial and is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link&amp;anchor=H21#H21\">",
"       \"Acute traumatic spinal cord injury\", section on 'Glucocorticoids'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Definitive therapy should be based on the MRI findings and provided in consultation with a neurosurgeon with pediatric expertise. (See",
"      <a class=\"local\" href=\"#H26107927\">",
"       'Initial Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H990821\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/1\">",
"      Pang D, Wilberger JE Jr. Spinal cord injury without radiographic abnormalities in children. J Neurosurg 1982; 57:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/2\">",
"      Pang D. Spinal cord injury without radiographic abnormality in children, 2 decades later. Neurosurgery 2004; 55:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/3\">",
"      Yucesoy K, Yuksel KZ. SCIWORA in MRI era. Clin Neurol Neurosurg 2008; 110:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/4\">",
"      TAYLOR AR, BLACKWOOD W. Paraplegia in hyperextension cervical injuries with normal radiographic appearances. J Bone Joint Surg Br 1948; 30B:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/5\">",
"      LEVENTHAL HR. Birth injuries of the spinal cord. J Pediatr 1960; 56:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/6\">",
"      Abroms IF, Bresnan MJ, Zuckerman JE, et al. Cervical cord injuries secondary to hyperextension of the head in breech presentations. Obstet Gynecol 1973; 41:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/7\">",
"      Robles LA. Traumatic spinal cord infarction in a child: case report and review of literature. Surg Neurol 2007; 67:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/8\">",
"      Hendey GW, Wolfson AB, Mower WR, et al. Spinal cord injury without radiographic abnormality: results of the National Emergency X-Radiography Utilization Study in blunt cervical trauma. J Trauma 2002; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/9\">",
"      Cirak B, Ziegfeld S, Knight VM, et al. Spinal injuries in children. J Pediatr Surg 2004; 39:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/10\">",
"      Polk-Williams A, Carr BG, Blinman TA, et al. Cervical spine injury in young children: a National Trauma Data Bank review. J Pediatr Surg 2008; 43:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/11\">",
"      Bosch PP, Vogt MT, Ward WT. Pediatric spinal cord injury without radiographic abnormality (SCIWORA): the absence of occult instability and lack of indication for bracing. Spine (Phila Pa 1976) 2002; 27:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/12\">",
"      Martin BW, Dykes E, Lecky FE. Patterns and risks in spinal trauma. Arch Dis Child 2004; 89:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/13\">",
"      Brown RL, Brunn MA, Garcia VF. Cervical spine injuries in children: a review of 103 patients treated consecutively at a level 1 pediatric trauma center. J Pediatr Surg 2001; 36:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/14\">",
"      Pang D, Pollack IF. Spinal cord injury without radiographic abnormality in children--the SCIWORA syndrome. J Trauma 1989; 29:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/15\">",
"      Hamilton MG, Myles ST. Pediatric spinal injury: review of 174 hospital admissions. J Neurosurg 1992; 77:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/16\">",
"      Osenbach RK, Menezes AH. Spinal cord injury without radiographic abnormality in children. Pediatr Neurosci 1989; 15:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/17\">",
"      Hall DE, Boydston W. Pediatric neck injuries. Pediatr Rev 1999; 20:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/18\">",
"      Peclet MH, Newman KD, Eichelberger MR, et al. Patterns of injury in children. J Pediatr Surg 1990; 25:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/19\">",
"      Grabb PA, Pang D. Magnetic resonance imaging in the evaluation of spinal cord injury without radiographic abnormality in children. Neurosurgery 1994; 35:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/20\">",
"      Felsberg GJ, Tien RD, Osumi AK, Cardenas CA. Utility of MR imaging in pediatric spinal cord injury. Pediatr Radiol 1995; 25:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/21\">",
"      Matsumura A, Meguro K, Tsurushima H, et al. Magnetic resonance imaging of spinal cord injury without radiologic abnormality. Surg Neurol 1990; 33:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/22\">",
"      Liao CC, Lui TN, Chen LR, et al. Spinal cord injury without radiological abnormality in preschool-aged children: correlation of magnetic resonance imaging findings with neurological outcomes. J Neurosurg 2005; 103:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/23\">",
"      Davis PC, Reisner A, Hudgins PA, et al. Spinal injuries in children: role of MR. AJNR Am J Neuroradiol 1993; 14:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4951/abstract/24\">",
"      Launay F, Leet AI, Sponseller PD. Pediatric spinal cord injury without radiographic abnormality: a meta-analysis. Clin Orthop Relat Res 2005; :166.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15603 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4951=[""].join("\n");
var outline_f4_53_4951=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26108436\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12191439\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26108408\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7632003\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H991129\">",
"      Mechanism of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26107899\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26107906\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26107920\">",
"      RADIOLOGIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26107927\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H990821\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26108436\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=related_link\">",
"      Evaluation and acute management of cervical spinal column injuries in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23689?source=related_link\">",
"      Overview of cervical spinal cord and cervical peripheral nerve injuries in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_53_4952="Overview of pulmonary function testing in adults";
var content_f4_53_4952=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of pulmonary function testing in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/53/4952/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/53/4952/contributors\">",
"     Paul L Enright, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/53/4952/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/53/4952/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/53/4952/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/53/4952/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/53/4952/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of pulmonary function is important in many clinical situations, both when the patient has a history or symptoms suggestive of lung disease, and when risk factors for lung disease are present, such as cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/1\">",
"     1",
"    </a>",
"    ]. An overview of pulmonary function testing will be presented here, summarizing the types of pulmonary function tests and their indications. Specific aspects of pulmonary function testing are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link\">",
"     \"Office spirometry\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9141?source=see_link\">",
"     \"Reference values for pulmonary function testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PULMONARY FUNCTION TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major types of pulmonary function tests include spirometry, measurement of lung volumes, and quantitation of diffusing capacity. Measurements of maximal respiratory pressures and flow-volume loops, which record forced inspiratory and expiratory flow rates, are also useful in specific clinical circumstances (",
"    <a class=\"graphic graphic_table graphicRef52884 \" href=\"UTD.htm?28/50/29484\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry, which includes measurement of forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) and forced vital capacity (FVC), is the most readily available and most useful pulmonary function test. It takes 10 to 15 minutes, uses a $2000 instrument, and carries no risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link\">",
"     \"Office spirometry\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The slow vital capacity (SVC) can also be measured with spirometers which collect data for at least 30 seconds. The SVC may be a useful measurement when the forced vital capacity (FVC) is reduced and airways obstruction is present. Slow exhalation results in a lesser degree of airway narrowing, and the patient may produce a larger, even normal vital capacity. In contrast, the vital capacity with restrictive disease is reduced during both slow and fast maneuvers. Thus, if the slow or forced vital capacity is within the normal range, it is generally unnecessary to measure static lung volumes (residual volume and total lung capacity) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Flow-volume loop",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flow-volume loops, which include forced inspiratory and expiratory maneuvers, should be performed whenever stridor is heard over the neck during forced breathing or for evaluation of unexplained dyspnea. Airway obstruction located in the pharynx, larynx, or trachea (upper airways) is usually impossible to detect from standard FVC maneuvers. Reproducible forced inspiratory vital capacity (FIVC) maneuvers may detect variable upper airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/3\">",
"     3",
"    </a>",
"    ], as can be seen with vocal cord paralysis or dysfunction, which causes a characteristic limitation of flow (plateau) during forced inhalation but little if any obstruction during exhalation (",
"    <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less commonly, a fixed upper airway obstruction (UAO) (eg, tracheal stenosis) causes flow limitation during both forced inhalation and forced exhalation maneuvers (",
"    <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"     figure 1",
"    </a>",
"    ). However, the flow-volume loop is not sensitive for detecting a fixed UAO, since the tracheal lumen is often reduced to less than 1 cm before a plateau is recognized. Poor effort mimics the flow-volume loop shapes of upper airway obstruction, but can be excluded when three or more maneuvers are seen to be reproducible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Post-bronchodilator",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    by metered-dose inhaler (MDI) is indicated during an initial workup if baseline spirometry demonstrates airway obstruction or if one suspects asthma. Spirometry should be repeated ten minutes after administration of a bronchodilator; proper MDI technique is important to prevent false negative results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a patient with airway obstruction, an increase in the FEV",
"    <sub>",
"     1",
"    </sub>",
"    of more than 12 percent and greater than 0.2 L suggests acute bronchodilator responsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the lack of an acute bronchodilator response should not preclude a six to eight week therapeutic trial of bronchodilators",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inhaled glucocorticoids, with reassessment of clinical status and change in FEV",
"    <sub>",
"     1",
"    </sub>",
"    at the end of that time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lung volumes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common lung volume measurements include total lung capacity (TLC), functional residual capacity (FRC), and residual volume (RV) (",
"    <a class=\"graphic graphic_figure graphicRef55440 \" href=\"UTD.htm?38/28/39373\">",
"     figure 2",
"    </a>",
"    ). Measurement of the total lung capacity (TLC) may be helpful when the vital capacity is decreased. For example, in the setting of chronic obstructive pulmonary disease (COPD) with a low vital capacity, measurement of the TLC can help determine if there is a superimposed restrictive disorder.",
"   </p>",
"   <p>",
"    There are four methods of measuring TLC:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Helium dilution",
"     </li>",
"     <li>",
"      Nitrogen washout",
"     </li>",
"     <li>",
"      Body plethysmography",
"     </li>",
"     <li>",
"      Chest radiograph measurements",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first two methods are used extensively in hospital pulmonary function laboratories, but they may underestimate the TLC in patients with moderate to severe COPD. The gold standard for measurement of TLC, particularly in the setting of significant airflow obstruction, is body plethysmography.",
"   </p>",
"   <p>",
"    Measurements of TLC using the chest radiograph or high resolution computed tomography (HRCT) correlate within 15 percent of those obtained by body plethysmography [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Since the TLC is equivalent to the amount of air seen in the lungs on a chest radiograph taken at maximal inspiration, it is important that the subject inhales maximally as the image is created.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Maximal respiratory pressures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of maximal inspiratory and expiratory pressures is indicated whenever there is an unexplained decrease in vital capacity or respiratory muscle weakness is suspected clinically. Maximal inspiratory pressure (MIP) is the maximal pressure that can be produced by the patient trying to inhale through a blocked mouthpiece. Maximal expiratory pressure (MEP) is the maximal pressure measured during forced expiration (with cheeks bulging) through a blocked mouthpiece after a full inhalation. Repeated measurements of MIP and MEP are useful in following the course of patients with neuromuscular disorders. The slow vital capacity may also be followed, but it is less specific and usually less sensitive.",
"   </p>",
"   <p>",
"    Maximal inspiratory and expiratory pressures are easily measured using a simple mechanical pressure gauge connected to a mouthpiece. MIP measures the ability of the diaphragm and the other respiratory muscles to generate inspiratory force, reflected by a negative airway pressure. The average MIP and MEP for adult men are -100 and +170 cm H2O, respectively, while the corresponding values for adult women are about -70 and +110 cm H2O, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The lower limit of the normal range is about two-thirds of these values [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91879305\">",
"    <span class=\"h2\">",
"     Diffusing capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the single-breath diffusing capacity for carbon monoxide (DLCO) is quick, safe, and useful in the evaluation of both restrictive and obstructive disease. It requires use of a piece of equipment that costs $20,000. In the setting of restrictive disease, the diffusing capacity helps distinguish between intrinsic lung disease, in which DLCO is usually reduced, from other causes of restriction, in which DLCO is usually normal. In the setting of obstructive disease, the DLCO helps distinguish between emphysema and other causes of chronic airway obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Oxygen desaturation during exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;The six-minute walk test (6MWT) is a good index of physical function and therapeutic response in patients with chronic lung disease, such as COPD or pulmonary fibrosis, or pulmonary arterial hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. A fall in SpO",
"    <sub>",
"     2",
"    </sub>",
"    of more than 4 percent (ending below 93 percent) suggests significant desaturation, and confirmation with arterial blood gas (ABG) measurements may be indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link\">",
"     \"Pulse oximetry\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During a 6MWT, healthy subjects can typically walk 400 to 700 m [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/9,13\">",
"     9,13",
"    </a>",
"    ]. An improvement of more than 70 m in distance walked appears to be clinically important and noticeable to patients. Estimates of the minimum decrease in distance walked that are important to patients range from 24 to 54 m [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/10,14,15\">",
"     10,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oxygen saturation during the 6MWT can also be used to titrate the amount of oxygen needed to maintain adequate saturation during walking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91879345\">",
"    <span class=\"h2\">",
"     Arterial blood gases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial blood gases (ABGs) may be a helpful adjunct to pulmonary function testing in selected patients. The primary role of measuring ABGs in stable outpatients is to confirm hypoventilation when it is suspected on the basis of clinical history (eg, respiratory muscle weakness, advanced COPD), an elevated serum bicarbonate level,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic hypoxemia. ABGs also provide a more accurate assessment of the severity of hypoxemia in patients who have low normal oxyhemoglobin saturation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function testing is useful for evaluation of a variety of forms of lung disease or for assessing the presence of disease in a patient with known risk factors, such as smoking. Other indications for pulmonary function tests include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation of symptoms such as chronic persistent cough, wheezing, dyspnea, and exertional cough or chest pain",
"     </li>",
"     <li>",
"      Objective assessment of bronchodilator therapy",
"     </li>",
"     <li>",
"      Evaluation of effects of exposure to dusts or chemicals at work",
"     </li>",
"     <li>",
"      Risk evaluation of patients prior to thoracic or upper abdominal surgery",
"     </li>",
"     <li>",
"      Objective assessment of impairment or disability",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chronic dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many lung diseases begin slowly and insidiously and finally manifest themselves with the nonspecific symptom of dyspnea on exertion. Pulmonary function tests are an essential part of the workup of such patients. In the outpatient setting, in which several days to weeks are available to make the diagnosis, a cost efficient method of ordering pulmonary function tests is to start with spirometry and then order further tests in a stepwise fashion to refine the diagnosis (",
"    <a class=\"graphic graphic_algorithm graphicRef67095 \" href=\"UTD.htm?18/27/18878\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a patient is hospitalized and a diagnosis is needed within a day or two, a battery of pulmonary function tests may be ordered, often including spirometry before and after (pre- and post-) bronchodilator therapy, static lung volumes, and diffusing capacity. If the cause of dyspnea on exertion remains uncertain after these tests have been performed, cardiopulmonary exercise testing should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry before and after a bronchodilator is indicated during the initial workup of patients suspected of having asthma (",
"    <a class=\"graphic graphic_figure graphicRef72469 graphicRef59123 \" href=\"UTD.htm?19/44/20175\">",
"     figure 3A-B",
"    </a>",
"    ). Spirometry is also indicated during most follow-up office visits to provide an objective measure of the therapeutic response [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cough or chest tightness with exercise or exposure to cold air, dusts, or fumes suggests bronchial hyperresponsiveness (BHR). However, BHR may not be detected by pre- and post-bronchodilator spirometry if the patient is asymptomatic at the time of evaluation. Commonly, the patient is asked to return for retesting when symptoms occur; however, this delays the diagnosis and may be impractical. Inhalation challenge testing can increase or decrease the pretest probability of asthma in less than an hour. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative to inhalation challenge testing for the detection of airway hyperreactivity is measurement of airway lability for two weeks in the patient's own environment, using ambulatory monitoring of peak flow or FEV",
"    <sub>",
"     1",
"    </sub>",
"    . Children with asthma (not controlled by medication) typically demonstrate peak flow lability",
"    <span class=\"nowrap\">",
"     (amplitude/mean)",
"    </span>",
"    in excess of 30 percent, while adults with active asthma have PEF lability greater than 20 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A forced inspiratory maneuver performed as part of a flow-volume loop may be useful in detecting \"vocal cord dysfunction\" in atypical patients with a diagnosis of asthma who do not respond appropriately to therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36613?source=see_link\">",
"     \"Diagnosis of wheezing illnesses other than asthma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link\">",
"     \"Paradoxical vocal cord motion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chronic obstructive pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry is the best method to detect or confirm airways obstruction in smokers with dyspnea (",
"    <a class=\"graphic graphic_figure graphicRef72469 graphicRef59123 \" href=\"UTD.htm?19/44/20175\">",
"     figure 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In these cases, the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio and the FEV",
"    <sub>",
"     1",
"    </sub>",
"    are decreased. Traditionally, values below 70 percent for the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio and below 80 percent predicted for the FEV",
"    <sub>",
"     1",
"    </sub>",
"    were used to define airflow obstruction. However, several studies suggest that use of fixed thresholds lead to misclassification, particularly in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Using the fifth percentile lower limit of normal (LLN) instead of the fixed value avoids misclassification of asymptomatic patients as having COPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link&amp;anchor=H11#H11\">",
"     \"Office spirometry\", section on 'Ratio of FEV1/FVC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of lung volumes is rarely useful in patients with obstructive spirometric parameters because it does not allow reliable differentiation of asthma and chronic obstructive pulmonary disease, and a concomitant restrictive ventilatory defect is detected in less than 10 percent of patients with a reduced FVC [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the diagnosis of COPD is established, the course and response to therapy may be followed by observing changes in the FEV",
"    <sub>",
"     1",
"    </sub>",
"    , as was done in the multicenter Lung Health Study [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/23\">",
"     23",
"    </a>",
"    ]. Continued smoking in a patient with airways obstruction often results in an abnormally rapid decline in FEV",
"    <sub>",
"     1",
"    </sub>",
"    (90 to 150",
"    <span class=\"nowrap\">",
"     mL/yr).",
"    </span>",
"    On the other hand, smoking cessation often results in an increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    during the first year, followed by a nearly normal rate of FEV",
"    <sub>",
"     1",
"    </sub>",
"    decline (30",
"    <span class=\"nowrap\">",
"     mL/yr).",
"    </span>",
"    Both a low FEV",
"    <sub>",
"     1",
"    </sub>",
"    and chronic mucus hypersecretion are predictors of hospitalization due to COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the airways obstruction due to COPD has become very severe, with an FEV",
"    <sub>",
"     1",
"    </sub>",
"    of 0.7 L or less, changes from visit to visit are usually within the error of the measurement (0.2 liters). In this circumstance, measurements of oxygen saturation during exercise and distance walked during six minutes may be more clinically meaningful for evaluating disease progression or therapeutic response than are changes in spirometry values [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/11,25\">",
"     11,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurement of the diffusing capacity for carbon monoxide helps to distinguish between emphysema and other causes of chronic airway obstruction. As an example, emphysema lowers the DLCO, obstructive chronic bronchitis does not affect the DLCO, and asthma frequently increases the DLCO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    .) Changes in the DLCO in patients with established, smoking-related COPD are probably not clinically useful during follow-up visits, unless dyspnea suddenly worsens without an obvious cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Restrictive lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The many disorders which cause reduction of lung volumes (restriction) may be divided into three groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intrinsic lung diseases, which cause inflammation or scarring of the lung tissue (interstitial lung disease) or fill the airspaces with exudate or debris (acute pneumonitis)",
"     </li>",
"     <li>",
"      Extrinsic disorders, such as disorders of the chest wall or the pleura, which mechanically compress the lungs or limit their expansion",
"     </li>",
"     <li>",
"      Neuromuscular disorders, which decrease the ability of the respiratory muscles to inflate and deflate the lungs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The history, physical examination, and chest radiograph are often helpful in distinguishing among these disorders. Spirometry is useful in detecting restriction (reduction) of lung volumes and assessing severity of impairment (",
"    <a class=\"graphic graphic_figure graphicRef72469 graphicRef59123 \" href=\"UTD.htm?19/44/20175\">",
"     figure 3A-B",
"    </a>",
"    ). Patients with mild interstitial lung disease may have normal values for FVC and TLC [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The DLCO is useful for differentiating intrinsic lung diseases, in which DLCO is generally reduced, from other causes of lung volume restriction, including neuromuscular disease or musculoskeletal deformity, in which DLCO is generally normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Changes in the DLCO are also useful for following the course of or response to therapy in patients with interstitial lung disease. Pulse oximetry during a 6MWT is also useful in this setting, since oxygen saturation often falls during mild exercise in patients with interstitial lung disease and responds to successful therapeutic interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Preoperative testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry is useful for determining the risk of postoperative pulmonary complications in certain high-risk situations, including patients known to have COPD or asthma, current smokers, and those scheduled for thoracic or upper abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/28\">",
"     28",
"    </a>",
"    ]. The degree of airways obstruction (or an elevated PCO",
"    <sub>",
"     2",
"    </sub>",
"    for patients with COPD) predicts the risk of postoperative pulmonary complications, such as atelectasis, pneumonia, and the need for prolonged mechanical ventilation. If spirometry demonstrates moderate to severe obstruction and the surgery can be delayed, a prophylactic program of pulmonary hygiene, including smoking cessation, inhaled bronchodilators or steroids, and antibiotics for bronchitis, will reduce the risk. However, the results of spirometry should not be used to deny surgery. Combining the results of spirometry with radioisotope or CT lung scans is also useful for predicting the remaining lung function following a lobectomy or pneumonectomy.",
"   </p>",
"   <p>",
"    A number of studies indicate that the maximum oxygen uptake (as a percent of predicted), determined by cardiopulmonary exercise testing, is better than spirometry for predicting postsurgical complications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/29\">",
"     29",
"    </a>",
"    ], but the cost:benefit ratio is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=see_link\">",
"     \"Preoperative evaluation for lung resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Impairment or disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most schemes for evaluation of respiratory impairment use pulmonary function tests, but the results in studies performed at rest are only a rough indication of an individual's ability to perform a given job. It is ideal to measure maximal oxygen consumption (VO",
"    <sub>",
"     2",
"    </sub>",
"    max), but this test is often not available to the primary care physicians who perform \"disability\" testing, or the expense is not reimbursed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Medical Association provides guidelines for the classification of respiratory impairment based upon the results of spirometry or maximal oxygen consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/32\">",
"     32",
"    </a>",
"    ]. Of course, the results must be of good quality. Severe impairment (AMA class 4 with estimated 50 to 100 percent impairment) is defined as any one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dyspnea after walking less than 100 meters on level ground",
"     </li>",
"     <li>",
"      FVC less than 50 percent predicted",
"     </li>",
"     <li>",
"      FEV",
"      <sub>",
"       1",
"      </sub>",
"      less than 40 percent predicted",
"     </li>",
"     <li>",
"      DLCO less than 40 percent predicted",
"     </li>",
"     <li>",
"      VO",
"      <sub>",
"       2",
"      </sub>",
"      max less than 15",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per min",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Social Security Administration defines total respiratory disability using either height-corrected FEV",
"    <sub>",
"     1",
"    </sub>",
"    (1.1 to 1.4 L) or a DLCO less than 30 percent predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4952/abstract/33\">",
"     33",
"    </a>",
"    ]. In one study, approximately 33 percent of patients who met the above criteria were dead after four years, compared with 7 percent of those who applied for disability but did not meet these criteria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32391?source=see_link\">",
"     \"Evaluation of pulmonary disability\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=see_link\">",
"       \"Patient information: Breathing tests (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary function testing is indicated for evaluation of respiratory symptoms (eg, cough, wheezing, dyspnea, chest pain), bronchodilator therapy, effect of workplace exposure to dust or chemicals, and disability. It can also be used to assess severity and progression of lung diseases, such as asthma, chronic obstructive lung disease, and various restrictive diseases. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major types of pulmonary function tests (PFTs) include spirometry, lung volumes, and diffusing capacity. Other PFTs include flow-volume loops (which record forced inspiratory and expiratory flow rates) and measurements of maximal respiratory pressures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pulmonary function tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) and forced vital capacity (FVC) are the primary measurements obtained by spirometry. Their ratio",
"      <span class=\"nowrap\">",
"       (FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC)",
"      </span>",
"      is important for distinguishing obstructive airways disease and restrictive disease. A reduced ratio suggests obstructive airway disease and a normal ratio suggests restrictive disease, if accompanied by reduced lung volumes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Spirometry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flow-volume loops can identify upper airway obstruction, which can be impossible to detect from standard FVC measurements. A characteristic limitation of flow (ie, a plateau) during forced inhalation suggests variable extrathoracic obstruction, while limitation of flow during forced exhalation suggests variable intrathoracic obstruction (",
"      <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"       figure 1",
"      </a>",
"      ). Fixed upper airway obstruction causes flow limitation during both forced inhalation and forced exhalation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"       \"Flow-volume loops\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spirometry before and after the administration of a bronchodilator can be performed to detect bronchodilator responsiveness. An increase in the FEV",
"      <sub>",
"       1",
"      </sub>",
"      of more than 12 percent and greater than 0.2 L suggests bronchodilator responsiveness; however, the lack of a bronchodilator response should not preclude a therapeutic trial of bronchodilators",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inhaled glucocorticoids. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Post-bronchodilator'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurement of lung volumes complements spirometry. Common measurements include total lung capacity (TLC), functional residual capacity (FRC), and residual volume (RV). Decreased lung volumes suggest restrictive disease if accompanied by a normal",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      ratio. Increased lung volumes suggest static hyperinflation due to obstructive airways disease if accompanied by decreased",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      ratio. Coexisting restriction and obstruction can be detected, but requires both spirometry and lung volumes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lung volumes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurement of diffusing capacity for carbon monoxide (DLCO) assesses gas exchange. Decreased DLCO accompanied by restrictive disease suggests intrinsic lung disease, whereas normal DLCO accompanied by restrictive disease suggests a non-pulmonary cause of restriction. Markedly decreased DLCO accompanied by obstructive airways disease suggests emphysema, whereas normal or mildly decreased DLCO suggests an alternative cause of obstructive airways disease. (See",
"      <a class=\"local\" href=\"#H91879305\">",
"       'Diffusing capacity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurement of maximal inspiratory and expiratory pressures detects respiratory muscle weakness. Maximal inspiratory pressure (MIP) is the maximal pressure that can be produced by the patient trying to inhale through a blocked mouthpiece. Maximal expiratory pressure (MEP) is the maximal pressure measured during forced expiration through a blocked mouthpiece after a full inhalation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Maximal respiratory pressures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulse oximetry is used to screen for oxygen desaturation in patients with exercise limitation and to determine the adequacy of supplemental oxygen therapy. A fall of more than 4 percent (ending at a saturation below 93 percent) suggests significant desaturation, which can be confirmed with arterial blood gas measurements. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Oxygen desaturation during exercise'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/1\">",
"      Crapo RO. Pulmonary-function testing. N Engl J Med 1994; 331:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/2\">",
"      Aaron SD, Dales RE, Cardinal P. How accurate is spirometry at predicting restrictive pulmonary impairment? Chest 1999; 115:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/3\">",
"      Modrykamien AM, Gudavalli R, McCarthy K, et al. Detection of upper airway obstruction with spirometry results and the flow-volume loop: a comparison of quantitative and visual inspection criteria. Respir Care 2009; 54:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/4\">",
"      Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/5\">",
"      Brown MS, McNitt-Gray MF, Goldin JG, et al. Automated measurement of single and total lung volume from CT. J Comput Assist Tomogr 1999; 23:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/6\">",
"      Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011; 364:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/7\">",
"      Bruschi C, Cerveri I, Zoia MC, et al. Reference values of maximal respiratory mouth pressures: a population-based study. Am Rev Respir Dis 1992; 146:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/8\">",
"      Enright PL, Kronmal RA, Manolio TA, et al. Respiratory muscle strength in the elderly. Correlates and reference values. Cardiovascular Health Study Research Group. Am J Respir Crit Care Med 1994; 149:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/9\">",
"      Enright PL. The six-minute walk test. Respir Care 2003; 48:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/10\">",
"      Swigris JJ, Wamboldt FS, Behr J, et al. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010; 65:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/11\">",
"      ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/12\">",
"      Swigris JJ, Olson AL, Shlobin OA, et al. Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology 2011; 16:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/13\">",
"      Casanova C, Celli BR, Barria P, et al. The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J 2011; 37:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/14\">",
"      Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/15\">",
"      du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/16\">",
"      Feiner JR, Severinghaus JW, Bickler PE. Dark skin decreases the accuracy of pulse oximeters at low oxygen saturation: the effects of oximeter probe type and gender. Anesth Analg 2007; 105:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/17\">",
"      van der Molen T, &Oslash;strem A, Stallberg B, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of asthma. Prim Care Respir J 2006; 15:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/18\">",
"      Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest 2000; 117:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/19\">",
"      Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/20\">",
"      Miller MR, Quanjer PH, Swanney MP, et al. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. Chest 2011; 139:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/21\">",
"      Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008; 63:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/22\">",
"      Dykstra BJ, Scanlon PD, Kester MM, et al. Lung volumes in 4,774 patients with obstructive lung disease. Chest 1999; 115:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/23\">",
"      Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/24\">",
"      Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/25\">",
"      Leach, RM, Davidson, AC, Chinn, S, et al. Portable liquid oxygen and exercise ability in severe respiratory disability. Thorax 1992; 47:781. Erratum in Thorax 1993; 48:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/26\">",
"      Boros PW, Enright PL, Quanjer PH, et al. Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis. Eur Respir J 2010; 36:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/27\">",
"      Hadeli KO, Siegel EM, Sherrill DL, et al. Predictors of oxygen desaturation during submaximal exercise in 8,000 patients. Chest 2001; 120:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/28\">",
"      Zibrak JD, O'Donnell CR, Marton K. Indications for pulmonary function testing. Ann Intern Med 1990; 112:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/29\">",
"      Olsen GN. The evolving role of exercise testing prior to lung resection. Chest 1989; 95:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/30\">",
"      Evaluation of impairment/disability secondary to respiratory disorders. American Thoracic Society. Am Rev Respir Dis 1986; 133:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/31\">",
"      Harber, P, Rothenberg, LS. Controversial aspects of respiratory disability determination. Semin Respir Med 1986; 7:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/32\">",
"      Spieler EA, Barth PS, Burton JF Jr, et al. Recommendations to guide revision of the Guides to the Evaluation of Permanent Impairment. American Medical Association. JAMA 2000; 283:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4952/abstract/33\">",
"      Social Security Administration (SSA). Technical revisions to medical criteria for determinations of disability. Final rules. Fed Regist 2002; 67:20018.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6969 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-71903B288C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4952=[""].join("\n");
var outline_f4_53_4952=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PULMONARY FUNCTION TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Spirometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Flow-volume loop",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Post-bronchodilator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lung volumes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Maximal respiratory pressures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91879305\">",
"      Diffusing capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Oxygen desaturation during exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91879345\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chronic dyspnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Restrictive lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Preoperative testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Impairment or disability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6969\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6969|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/27/18878\" title=\"algorithm 1\">",
"      Evaluation of dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6969|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/31/35325\" title=\"figure 1\">",
"      Flow volume loops in airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/28/39373\" title=\"figure 2\">",
"      Lung volume and capacities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/26/16814\" title=\"figure 3A\">",
"      Severity obstructive dz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/12/31949\" title=\"figure 3B\">",
"      Severity restrictive dz",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6969|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/50/29484\" title=\"table 1\">",
"      Indications for pulmonary tests",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36613?source=related_link\">",
"      Diagnosis of wheezing illnesses other than asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32391?source=related_link\">",
"      Evaluation of pulmonary disability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=related_link\">",
"      Office spirometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=related_link\">",
"      Patient information: Breathing tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=related_link\">",
"      Preoperative evaluation for lung resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9141?source=related_link\">",
"      Reference values for pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=related_link\">",
"      The use of inhaler devices in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=related_link\">",
"      Use of pulmonary function testing in the diagnosis of asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_53_4953="Hairy cell leukemia spleen";
var content_f4_53_4953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F58853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F58853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hairy cell leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This splenic section from a patient with hairy cell leukemia shows infiltration with a monotonous population of medium-sized cells with clear cytoplasm and interlocking cell borders, giving a halo or \"fried egg\" appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14,1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4953=[""].join("\n");
var outline_f4_53_4953=null;
var title_f4_53_4954="Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis";
var content_f4_53_4954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/53/4954/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/53/4954/contributors\">",
"     Kevin R Krull, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/53/4954/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/53/4954/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/53/4954/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/53/4954/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/53/4954/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention deficit hyperactivity disorder (ADHD) is a disorder that manifests in early childhood with symptoms of hyperactivity, impulsivity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inattention. The symptoms affect cognitive, academic, behavioral, emotional, and social functioning (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review focuses on the epidemiology and pathogenesis of ADHD. The evaluation, diagnosis, management, and prognosis of ADHD in children and ADHD in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32761?source=see_link\">",
"     \"Adult attention deficit hyperactivity disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADHD is a disorder that manifests in early childhood with symptoms of hyperactivity, impulsivity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inattention. The symptoms affect cognitive, academic, behavioral, emotional, and social functioning (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link&amp;anchor=H830607547#H830607547\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link&amp;anchor=H2#H2\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Core symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of ADHD in children varies from 2 to 18 percent depending upon the diagnostic criteria and the population studied (eg, primary care versus referral) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/1-9\">",
"     1-9",
"    </a>",
"    ]. The prevalence in school-age children is estimated to be between 8 and 10 percent, making it one of the most common disorders of childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/2,3,6-8,10\">",
"     2,3,6-8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2007 National Survey of Children&rsquo;s Health (NSCH), the prevalence of a parent-reported diagnosis of ADHD among children aged 4 to 17 years of age in the United States was estimated to be 9.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/11\">",
"     11",
"    </a>",
"    ]. This is an increase from the estimated prevalence of 7.8 percent in 2003; in particular, the prevalence increased among Hispanic children and older adolescents. &nbsp;ADHD is more common in boys than girls (male to female ratio 4:1 for the predominantly hyperactive type and 2:1 for the predominantly inattentive type) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/3\">",
"     3",
"    </a>",
"    ]. In the 2007 NSCH, the prevalence was 13.2 in boys and 5.6 percent in girls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/11\">",
"     11",
"    </a>",
"    ]. The prevalence of ADHD increased with increasing age (6.6 percent in 4- to 10-year-olds; 11.2 percent among 11- to 14-year-olds; and 13.6 percent in 15- to 17-year-olds). Among those with reported ADHD, 66 percent were being treated with medication at the time of the survey.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Comorbid disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with ADHD frequently have comorbid psychiatric disorders, including (but not limited to) oppositional defiant disorder, conduct disorder, depression, anxiety disorder, and learning disabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/10,12-14\">",
"     10,12-14",
"    </a>",
"    ]. The comorbid conditions can be primary or secondary (eg, exacerbated by the ADHD). In either case, they require treatment independent of the treatment for ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link&amp;anchor=H22#H22\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Coexisting disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oppositional defiant disorder &ndash; Oppositional defiant disorder (ODD) frequently coexists with ADHD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/3,7\">",
"       3,7",
"      </a>",
"      ]. It is more common in the combined and hyperactive-impulsive subtypes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link&amp;anchor=H830608835#H830608835\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Subtypes of ADHD'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link&amp;anchor=H22#H22\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Coexisting disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Conduct&nbsp;disorder &ndash; Conduct disorder coexists with ADHD in approximately one-third of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/3,10\">",
"       3,10",
"      </a>",
"      ]. Like ODD, it is more common in the combined and hyperactive-impulsive subtypes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anxiety&nbsp;disorder &ndash; Anxiety disorder coexists with ADHD in approximately 20 to 30 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/3,7,10\">",
"       3,7,10",
"      </a>",
"      ]. It occurs more frequently in the inattentive subtype [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/3,15,16\">",
"       3,15,16",
"      </a>",
"      ]. Anxiety may develop as a secondary disorder in children with ADHD; however, in many cases, anxiety appears to be a distinct disorder and may be independent of ADHD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/12,17\">",
"       12,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Depression &ndash; Depression coexists with ADHD in as many as one-third of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/3,7,10\">",
"       3,7,10",
"      </a>",
"      ]. It appears be more common in the inattentive and combined subtypes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. Children with ADHD and comorbid mood disorder may have family members with a history of major depressive disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/14\">",
"       14",
"      </a>",
"      ]. Adolescents with ADHD and mood disorder are at increased risk for attempting suicide [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"       \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"       \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Learning disability &ndash; Estimates for the coexistence of learning disorders and ADHD range from 20 to 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/3,10,21,22\">",
"       3,10,21,22",
"      </a>",
"      ]. In a population-based birth cohort, approximately 40 percent of children with ADHD also had reading disability, and approximately 60 percent of children with ADHD also had written-language disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. Learning disabilities appear to occur more commonly among children with the inattentive and combined types of ADHD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=see_link&amp;anchor=H18#H18\">",
"       \"Specific learning disabilities in children: Clinical features\", section on 'Comorbidities'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Data regarding the rates of coexistence of specific types of learning disabilities and ADHD are lacking. In a study of 445 ninth-grade students, children with reading disabilities were twice as likely to meet diagnostic criteria for inattention than the general population (15 versus 7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/24\">",
"       24",
"      </a>",
"      ]. Conversely, individuals with ADHD were at higher risk than the general population for reading disability or phonologic awareness deficit (36 versus 17 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6409?source=see_link\">",
"       \"Normal reading development and etiology of reading difficulty in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/21/1370?source=see_link\">",
"       \"Clinical features and evaluation of reading difficulty in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS: PRIMARY FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of ADHD is not definitively known. A genetic imbalance of catecholamine metabolism in the cerebral cortex appears to play a primary role, as illustrated by structural and functional brain imaging, animal studies, and the response to drugs with noradrenergic activity (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/7,25-27\">",
"     7,25-27",
"    </a>",
"    ]. However, various environmental factors may play a secondary role; the significance of environmental factors is controversial. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Pathogenesis: potential environmental influences'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for a genetic basis of ADHD is supported by twin studies that demonstrate concordance as high as 92 percent in monozygotic twins and 33 percent in dizygotic twins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/28-33\">",
"     28-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family-based and case-control studies have identified a number of genes that appear to play a role in the development of ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dopamine D2, D4, and D5 receptor genes (",
"      <em>",
"       DRD2",
"      </em>",
"      ,",
"      <em>",
"       DRD4",
"      </em>",
"      , and",
"      <em>",
"       DRD5",
"      </em>",
"      )",
"     </li>",
"     <li>",
"      Serotonin transporter genes (",
"      <em>",
"       SLC6A3",
"      </em>",
"      and",
"      <em>",
"       SLC6A4",
"      </em>",
"      )",
"     </li>",
"     <li>",
"      Serotonin 1B receptor (",
"      <em>",
"       HTR1B",
"      </em>",
"      ) gene",
"     </li>",
"     <li>",
"      Dopamine beta-hydroxylase (",
"      <em>",
"       DBH",
"      </em>",
"      ) gene",
"     </li>",
"     <li>",
"      Synaptosomal-associated protein of 25 kDa (",
"      <em>",
"       SNAP25",
"      </em>",
"      )",
"     </li>",
"     <li>",
"      Glutamate receptor, metabotropic gene (",
"      <em>",
"       GRM1",
"      </em>",
"      ,",
"      <em>",
"       GRM5",
"      </em>",
"      ,",
"      <em>",
"       GRM7",
"      </em>",
"      ,",
"      <em>",
"       GRM8",
"      </em>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional support for a genetic contribution to ADHD is provided by a case-control study in which children with ADHD had a higher rate of copy number variations (CNVs) than controls (15.6 versus 7.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/39\">",
"     39",
"    </a>",
"    ]. CNVs are DNA segments whose copy number varies between different individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of genetic variation\", section on 'Copy number variations (CNVs)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neuroanatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural brain imaging in children with and without ADHD demonstrates significant differences in many areas. Those with ADHD have reversed or absent asymmetry of the caudate nucleus, smaller cerebral and cerebellar volume, smaller posterior corpus callosum regions, and increased gray matter in the posterior temporal and inferior parietal cortices [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Differences are particularly noted in anterior brain areas, including smaller prefrontal cortical volumes and reduced thickness of the anterior cingulate cortex, as well as cortical thinning in bilateral superior frontal brain regions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/43-46\">",
"     43-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functional brain imaging reveals that children with ADHD have reduced global activation and reduced local activation in the area of the basal ganglia and anterior frontal lobe [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. The administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    affects activation in these areas. However, the effect varies depending upon the area and whether the child has ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/52\">",
"     52",
"    </a>",
"    ]. These findings support the hypothesis that ADHD is characterized by atypical frontal-striatal function and that methylphenidate affects striatal activation differently in ADHD than in healthy children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Clinical correlation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropsychologic testing suggests that patients with ADHD have impaired executive functions (processes involved in forward planning, including abstract reasoning, mental flexibility, working memory)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    difficulties with response inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. These findings are consistent with neuroimaging studies that demonstrate structural and functional abnormalities in prefrontal structures and basal ganglia regions (which underlie motor response inhibition and executive functions) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Catecholamine metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animal studies, the noradrenergic system is involved in the modulation of higher cortical functions, including attention, alertness, vigilance, and executive function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/57\">",
"     57",
"    </a>",
"    ]. Rat models suggest that an imbalance between the norepinephrine and dopamine systems in the prefrontal cortex contributes to the pathogenesis of ADHD (decrease in inhibitory dopaminergic activity and increase in norepinephrine activity) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings from animal studies are supported by human studies indicating patients with ADHD have an increase in dopamine transporter density (which may clear dopamine from the synapse too quickly) compared to healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/59\">",
"     59",
"    </a>",
"    ] and that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    increases extracellular dopamine in the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOGENESIS: POTENTIAL ENVIRONMENTAL INFLUENCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various environmental factors may play a secondary role in the pathogenesis of ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/25-27,61\">",
"     25-27,61",
"    </a>",
"    ]. The significance of environmental factors is controversial.",
"   </p>",
"   <p>",
"    When considering the contribution of environmental factors, it is important to distinguish between the behavioral symptoms of ADHD and the clinical syndrome of ADHD (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ). Inattentiveness, impulsivity, and hyperactivity occur to some extent in all children. It is the persistence, pervasiveness, and functional complications of the behavioral symptoms that lead to a diagnosis of ADHD. To meet criteria for ADHD, symptoms must [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Be present in more than one setting (eg, school and home)",
"     </li>",
"     <li>",
"      Persist for at least six months",
"     </li>",
"     <li>",
"      Be present before the age of seven years",
"     </li>",
"     <li>",
"      Impair function in academic, social, or occupational activities",
"     </li>",
"     <li>",
"      Be excessive for the developmental level of the child",
"     </li>",
"     <li>",
"      Not be caused by other mental disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of ADHD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link&amp;anchor=H830607650#H830607650\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Diagnostic criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dietary influences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influence of diet on attention, hyperactivity, and behavior is controversial. Areas of investigation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Food additives (artificial colors, artificial flavors, preservatives)",
"     </li>",
"     <li>",
"      Refined sugar intake",
"     </li>",
"     <li>",
"      Food sensitivity (allergy or intolerance)",
"     </li>",
"     <li>",
"      Essential fatty acid deficiency",
"     </li>",
"     <li>",
"      Iron and zinc deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These dietary factors generally do not impact behavior to a clinically significant level and do not account for the majority of cases of ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/25,62\">",
"     25,62",
"    </a>",
"    ]. However, a small subset of children may demonstrate mild adverse behavioral effects of diets containing food additives, artificial colors, excess sugar, or reduced intake of essential fatty acids and minerals. Similarly, food sensitivity may be associated with behavioral abnormalities, but only infrequently with the clinical syndrome of ADHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link&amp;anchor=H830607650#H830607650\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The implications of these findings on the management of children with ADHD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link&amp;anchor=H192030975#H192030975\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\", section on 'Dietary interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Food additives",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of food additives (artificial colors and flavors, preservatives) on the behavior of children is an active area of investigation. The body of literature focusing on the behavioral effects of food additives suggests that some children (both with and without ADHD) may have identifiable sensitivity to specific additives [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/63-68\">",
"     63-68",
"    </a>",
"    ]. However, this conclusion is not universally accepted, and the issue remains controversial. In March 2011, the Food Advisory Committee of the United States Food and Drug Administration determined that existing data do not support a causal link between consumption of color additives and hyperactivity or other problematic behaviors in children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Food additives were first suggested as a potential cause of hyperactive behavior in the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/70\">",
"     70",
"    </a>",
"    ]. Studies that followed yielded mixed results. In a 2012 meta-analysis of five randomized crossover studies, restriction diets reduced ADHD symptoms in children (effect size 0.29, 95% CI 0.16-0.52) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/66\">",
"     66",
"    </a>",
"    ]. Masked challenge with specific food colors had a small effect on parent-reported ADHD symptoms (20 studies, 794 participants, effect size 0.18, 95% CI 0.08-0.29), and a non-significant effect on teacher-reported symptoms (10 studies, 323 participants effect size 0.07, 95% CI -0.03-0.18). This discrepancy between parent and health",
"    <span class=\"nowrap\">",
"     professional/teacher",
"    </span>",
"    report of symptoms has been noted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/63,71\">",
"     63,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these findings support a relationship between food additives and ADHD symptoms in some children, they do not prove that food additives cause ADHD. Major practice guidelines for the treatment of ADHD do not routinely recommend elimination of food additives in the management of children with ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/2,7,26,27\">",
"     2,7,26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link&amp;anchor=H450433671#H450433671\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\", section on 'Elimination diets'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Refined sugar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse behavior effects, including hyperactivity, are commonly attributed to excess sugar intake by parents and teachers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. There are two proposed mechanisms: an allergy to refined sugar and functional reactive hypoglycemia (which triggers release of stress hormones such as adrenaline) after ingesting sugar [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/64,74\">",
"     64,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 1995 meta-analysis of 23 studies in which sugar was eliminated from the diet",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    children were challenged with sugar failed to support an association between sugar intake and hyperactivity, attention span, or cognitive functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/75\">",
"     75",
"    </a>",
"    ]. However, a small effect of sugar on subsets of children could not be excluded. A 2005 systematic review that included a slightly different set of trials supported the conclusion of the earlier meta-analysis, but points out that most of the trials used relatively low-sugar challenges (equivalent to roughly one 16-ounce bottle of soda) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Food sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few well-designed trials evaluating the potential association between food sensitivity (allergy or intolerance) and behavior. Demonstration of such an association requires removal of the suspect food(s) from the child's diet (elimination diet) followed by challenge with the suspect food(s) versus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The oligoallergenic diet (OAD) is an example of an elimination diet that may be used to assess the relationship between food sensitivity and behavior. The OAD restricts intake to a few foods that are unlikely to cause allergy (eg, turkey, lamb, rice, potato, banana, apple, pear, a few vegetables, water, salt and pepper) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/64\">",
"     64",
"    </a>",
"    ]. Although parents and teachers must supervise the elimination diet, which precludes blinding during this stage, they can be blinded when the child is challenged with the suspect food(s).",
"   </p>",
"   <p>",
"    A review of double-blind placebo-controlled trials of the OAD in children with ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/76-79\">",
"     76-79",
"    </a>",
"    ] found that behavior improved during the elimination phase [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/64\">",
"     64",
"    </a>",
"    ]. However, behavior also improved during the placebo phases of the food challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/76-78\">",
"     76-78",
"    </a>",
"    ], or when the OAD diet was compared with a placebo diet (common foods with similar appearance to foods included in the OAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/79\">",
"     79",
"    </a>",
"    ]. The authors of the review concluded that some children may have identifiable sensitivities to certain foods. Nonetheless, food sensitivity plays no role in the majority of cases of ADHD.",
"   </p>",
"   <p>",
"    A subsequent randomized trial determined that the identification of foods that may be associated with ADHD symptoms cannot be achieved by measuring IgG levels, a common practice in complementary medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Essential fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essential fatty acids, which include the omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) and the omega-6 fatty acid, arachidonic acid, are necessary for the development and functioning of neuronal membranes.",
"   </p>",
"   <p>",
"    Some studies have noted decreased fatty acid concentrations in the serum of children with ADHD, suggesting that deficiency of essential fatty acids may play a role in the pathogenesis of ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/82-85\">",
"     82-85",
"    </a>",
"    ]. However, evidence that fatty acid supplementation improves ADHD symptoms is limited and the role of fatty acid supplementation in the pathogenesis of ADHD remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/68,86,87\">",
"     68,86,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link&amp;anchor=H450433678#H450433678\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\", section on 'Essential fatty acid supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of iron deficiency in ADHD has not been clearly defined. However, low serum ferritin has been associated with cognitive and learning disorders, and iron deficiency has been associated with abnormal dopaminergic neurotransmission (iron is a co-enzyme of dopamine synthesis) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Case-control studies of ferritin levels in children with ADHD have had inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/89-93\">",
"     89-93",
"    </a>",
"    ], as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, mean serum ferritin levels (but not serum iron, hemoglobin, or hematocrit) were lower among 23 children with ADHD than among 27 control children; children with ADHD were more likely than controls to have serum ferritin &lt;30",
"      <span class=\"nowrap\">",
"       ng/mL;",
"      </span>",
"      and decreased serum ferritin correlated with increased ADHD symptom severity on the Conners' parent rating scale [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/89\">",
"       89",
"      </a>",
"      ]. In a follow-up randomized controlled trial, iron supplementation in children with low serum ferritin was associated with improved ADHD symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/91\">",
"       91",
"      </a>",
"      ], the mean serum ferritin level of 68 children with ADHD did not differ from that of the control children in the study described above [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/90\">",
"       90",
"      </a>",
"      ], nor from that of the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/92\">",
"       92",
"      </a>",
"      ]. However, a greater proportion of children with ADHD had serum ferritin levels &lt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies are necessary to confirm or refute an association between iron deficiency and ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Zinc deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several controlled studies demonstrating zinc deficiency or a beneficial response to zinc supplementation in children with ADHD suggest that zinc deficiency may play a role in the pathogenesis of ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. Additional studies are necessary to confirm this hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/25,96\">",
"     25,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most studies, prenatal exposure to tobacco is associated with development of ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/97-104\">",
"     97-104",
"    </a>",
"    ]. Other factors that have been associated with the development of ADHD, but in which the association is inconsistent, include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/25,61\">",
"     25,61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prematurity and low birth weight [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/105-107\">",
"       105-107",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prenatal exposure to alcohol [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/98,103,108-110\">",
"       98,103,108-110",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Head trauma in young children [",
"      <a class=\"abstract\" href=\"UTD.htm?4/53/4954/abstract/111,112\">",
"       111,112",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/32/11778?source=see_link\">",
"       \"Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/8/33922?source=see_link\">",
"       \"Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attention deficit hyperactivity disorder (ADHD) is a disorder that manifests in early childhood with symptoms of hyperactivity, impulsivity,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inattention (",
"      <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of ADHD is estimated to be between 8 and 10 percent in school-age children; it is more common in boys than girls. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children and adolescents with ADHD frequently have comorbid psychiatric disorders, including oppositional defiant disorder, conduct disorder, depression, anxiety disorder, and learning disabilities. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Comorbid disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of ADHD is not definitively known. A genetic imbalance of catecholamine metabolism in the cerebral cortex appears to play a primary role. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathogenesis: primary factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various environmental factors may play a secondary role in the pathogenesis of ADHD; the significance of environmental factors is controversial. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pathogenesis: potential environmental influences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dietary factors (food additives, sugar, food sensitivity, essential fatty acid deficiency, mineral deficiency) generally do not impact behavior to a clinically significant level and do not account for the majority of cases of ADHD. However, a small subset of children may demonstrate mild adverse behavioral effects in response to dietary influences. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Dietary influences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prenatal exposure to tobacco is associated with development of ADHD. Other factors that have been associated with the development of ADHD, but in which the association is inconsistent, include prematurity and low birth weight, prenatal exposure to alcohol, and head trauma. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Other factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4th, American Psychiatric Association, Washington, DC 2000. p.85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/2\">",
"      Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128:1007.",
"     </a>",
"    </li>",
"    <li>",
"     Agency for Healthcare Research and Quality. Diagnosis of Attention-Deficit/Hyperactivity Disorder. Clinical Focus. Rockville, MD, October 1999. file://www.ahrq.gov/clinic/tp/adhddtp.htm (Accessed on October 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/4\">",
"      National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 2000; 39:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/5\">",
"      Barbaresi W, Katusic S, Colligan R, et al. How common is attention-deficit/hyperactivity disorder? Towards resolution of the controversy: results from a population-based study. Acta Paediatr Suppl 2004; 93:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/6\">",
"      Froehlich TE, Lanphear BP, Epstein JN, et al. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med 2007; 161:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/7\">",
"      Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/8\">",
"      Merikangas KR, He JP, Brody D, et al. Prevalence and treatment of mental disorders among US children in the 2001-2004 NHANES. Pediatrics 2010; 125:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/9\">",
"      Boyle CA, Boulet S, Schieve LA, et al. Trends in the prevalence of developmental disabilities in US children, 1997-2008. Pediatrics 2011; 127:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/10\">",
"      Larson K, Russ SA, Kahn RS, Halfon N. Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics 2011; 127:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children --- United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep 2010; 59:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/12\">",
"      Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001; 40:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/13\">",
"      Levy F, Hay DA, Bennett KS, McStephen M. Gender differences in ADHD subtype comorbidity. J Am Acad Child Adolesc Psychiatry 2005; 44:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/14\">",
"      Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991; 148:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/15\">",
"      Wolraich ML, Hannah JN, Pinnock TY, et al. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry 1996; 35:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/16\">",
"      Wolraich ML, Hannah JN, Baumgaertel A, Feurer ID. Examination of DSM-IV criteria for attention deficit/hyperactivity disorder in a county-wide sample. J Dev Behav Pediatr 1998; 19:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/17\">",
"      Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. J Clin Psychiatry 1998; 59 Suppl 7:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/18\">",
"      Lam LT. Attention deficit disorder and hospitalization owing to intra- and interpersonal violence among children and young adolescents. J Adolesc Health 2005; 36:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/19\">",
"      Brent DA, Perper JA, Goldstein CE, et al. Risk factors for adolescent suicide. A comparison of adolescent suicide victims with suicidal inpatients. Arch Gen Psychiatry 1988; 45:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/20\">",
"      Nasser EH, Overholser JC. Assessing varying degrees of lethality in depressed adolescent suicide attempters. Acta Psychiatr Scand 1999; 99:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/21\">",
"      Pliszka SR. Patterns of psychiatric comorbidity with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/22\">",
"      Yoshimasu K, Barbaresi WJ, Colligan RC, et al. Gender, attention-deficit/hyperactivity disorder, and reading disability in a population-based birth cohort. Pediatrics 2010; 126:e788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/23\">",
"      Yoshimasu K, Barbaresi WJ, Colligan RC, et al. Written-language disorder among children with and without ADHD in a population-based birth cohort. Pediatrics 2011; 128:e605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/24\">",
"      Shaywitz SE, Fletcher JM, Shaywitz BA. Issues in the definition and classification of attention deficit disorder. Top Lang Disord 1994; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/25\">",
"      Millichap JG. Etiologic classification of attention-deficit/hyperactivity disorder. Pediatrics 2008; 121:e358.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. 2008. file://www.nice.org.uk/CG72 (Accessed on October 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/27\">",
"      Taylor E, D&ouml;pfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder -- first upgrade. Eur Child Adolesc Psychiatry 2004; 13 Suppl 1:I7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/28\">",
"      Goodman R, Stevenson J. A twin study of hyperactivity--II. The aetiological role of genes, family relationships and perinatal adversity. J Child Psychol Psychiatry 1989; 30:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/29\">",
"      Gillis JJ, Gilger JW, Pennington BF, DeFries JC. Attention deficit disorder in reading-disabled twins: evidence for a genetic etiology. J Abnorm Child Psychol 1992; 20:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/30\">",
"      Neuman RJ, Heath A, Reich W, et al. Latent class analysis of ADHD and comorbid symptoms in a population sample of adolescent female twins. J Child Psychol Psychiatry 2001; 42:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/31\">",
"      Hechtman L. Families of children with attention deficit hyperactivity disorder: a review. Can J Psychiatry 1996; 41:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/32\">",
"      Stevenson J. Evidence for a genetic etiology in hyperactivity in children. Behav Genet 1992; 22:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/33\">",
"      Levy F, Hay DA, McStephen M, et al. Attention-deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. J Am Acad Child Adolesc Psychiatry 1997; 36:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/34\">",
"      Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/35\">",
"      Nyman ES, Ogdie MN, Loukola A, et al. ADHD candidate gene study in a population-based birth cohort: association with DBH and DRD2. J Am Acad Child Adolesc Psychiatry 2007; 46:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/36\">",
"      Elia J, Gai X, Xie HM, et al. Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol Psychiatry 2010; 15:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/37\">",
"      Elia J, Glessner JT, Wang K, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet 2012; 44:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/38\">",
"      Purper-Ouakil D, Ramoz N, Lepagnol-Bestel AM, et al. Neurobiology of attention deficit/hyperactivity disorder. Pediatr Res 2011; 69:69R.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/39\">",
"      Williams NM, Zaharieva I, Martin A, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet 2010; 376:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/40\">",
"      Giedd JN, Blumenthal J, Molloy E, Castellanos FX. Brain imaging of attention deficit/hyperactivity disorder. Ann N Y Acad Sci 2001; 931:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/41\">",
"      Castellanos FX, Lee PP, Sharp W, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 2002; 288:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/42\">",
"      Sowell ER, Thompson PM, Welcome SE, et al. Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet 2003; 362:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/43\">",
"      Seidman LJ, Valera EM, Makris N, et al. Dorsolateral prefrontal and anterior cingulate cortex volumetric abnormalities in adults with attention-deficit/hyperactivity disorder identified by magnetic resonance imaging. Biol Psychiatry 2006; 60:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/44\">",
"      Makris N, Biederman J, Valera EM, et al. Cortical thinning of the attention and executive function networks in adults with attention-deficit/hyperactivity disorder. Cereb Cortex 2007; 17:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/45\">",
"      Shaw P, Lerch J, Greenstein D, et al. Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2006; 63:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/46\">",
"      Dickstein SG, Bannon K, Castellanos FX, Milham MP. The neural correlates of attention deficit hyperactivity disorder: an ALE meta-analysis. J Child Psychol Psychiatry 2006; 47:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/47\">",
"      Bush G, Frazier JA, Rauch SL, et al. Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the Counting Stroop. Biol Psychiatry 1999; 45:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/48\">",
"      Rubia K, Overmeyer S, Taylor E, et al. Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry 1999; 156:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/49\">",
"      Rubia K, Smith AB, Brammer MJ, et al. Abnormal brain activation during inhibition and error detection in medication-naive adolescents with ADHD. Am J Psychiatry 2005; 162:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/50\">",
"      Zang YF, Jin Z, Weng XC, et al. Functional MRI in attention-deficit hyperactivity disorder: evidence for hypofrontality. Brain Dev 2005; 27:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/51\">",
"      Hart H, Radua J, Nakao T, et al. Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. JAMA Psychiatry 2013; 70:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/52\">",
"      Vaidya CJ, Austin G, Kirkorian G, et al. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci U S A 1998; 95:14494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/53\">",
"      Pennington BF, Ozonoff S. Executive functions and developmental psychopathology. J Child Psychol Psychiatry 1996; 37:51.",
"     </a>",
"    </li>",
"    <li>",
"     Barkley RA. Theories of attention-deficit/hyperactivity disorder. In: Handbook of Disruptive Behavior Disorders, Quay HC, Hogan AE (Eds), Kluwer Academic/Plenum, New York 1999. p.295.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/55\">",
"      Himelstein J, Newcorn JH, Halperin JM. The neurobiology of attention-deficit hyperactivity disorder. Front Biosci 2000; 5:D461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/56\">",
"      Tannock R. Attention deficit hyperactivity disorder: advances in cognitive, neurobiological, and genetic research. J Child Psychol Psychiatry 1998; 39:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/57\">",
"      Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999; 46:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/58\">",
"      Russell V, Allie S, Wiggins T. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder--the spontaneously hypertensive rat. Behav Brain Res 2000; 117:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/59\">",
"      Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999; 354:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/60\">",
"      Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21:RC121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/61\">",
"      Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr 2007; 96:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/62\">",
"      Barrett JR. Diet &amp; nutrition: hyperactive ingredients? Environ Health Perspect 2007; 115:A578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/63\">",
"      Schab DW, Trinh NH. Do artificial food colors promote hyperactivity in children with hyperactive syndromes? A meta-analysis of double-blind placebo-controlled trials. J Dev Behav Pediatr 2004; 25:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/64\">",
"      Rojas NL, Chan E. Old and new controversies in the alternative treatment of attention-deficit hyperactivity disorder. Ment Retard Dev Disabil Res Rev 2005; 11:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/65\">",
"      Stevens LJ, Kuczek T, Burgess JR, et al. Dietary sensitivities and ADHD symptoms: thirty-five years of research. Clin Pediatr (Phila) 2011; 50:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/66\">",
"      Nigg JT, Lewis K, Edinger T, Falk M. Meta-analysis of attention-deficit/hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives. J Am Acad Child Adolesc Psychiatry 2012; 51:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/67\">",
"      Millichap JG, Yee MM. The diet factor in attention-deficit/hyperactivity disorder. Pediatrics 2012; 129:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/68\">",
"      Sonuga-Barke EJ, Brandeis D, Cortese S, et al. Nonpharmacological Interventions for ADHD: Systematic Review and Meta-Analyses of Randomized Controlled Trials of Dietary and Psychological Treatments. Am J Psychiatry 2013; 170:275.",
"     </a>",
"    </li>",
"    <li>",
"     Quick Minutes: Food Advisory Committee Meeting March 30-31, 2011. file://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/FoodAdvisoryCommittee/ucm250901.htm (Accessed on May 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/70\">",
"      Feingold BF. Hyperkinesis and learning disabilities linked to artificial food flavors and colors. Am J Nurs 1975; 75:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/71\">",
"      Bateman B, Warner JO, Hutchinson E, et al. The effects of a double blind, placebo controlled, artificial food colourings and benzoate preservative challenge on hyperactivity in a general population sample of preschool children. Arch Dis Child 2004; 89:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/72\">",
"      Krummel DA, Seligson FH, Guthrie HA. Hyperactivity: is candy causal? Crit Rev Food Sci Nutr 1996; 36:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/73\">",
"      DiBattista D, Shepherd ML. Primary school teachers' beliefs and advice to parents concerning sugar consumption and activity in children. Psychol Rep 1993; 72:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/74\">",
"      Weber W, Newmark S. Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism. Pediatr Clin North Am 2007; 54:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/75\">",
"      Wolraich ML, Wilson DB, White JW. The effect of sugar on behavior or cognition in children. A meta-analysis. JAMA 1995; 274:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/76\">",
"      Egger J, Carter CM, Graham PJ, et al. Controlled trial of oligoantigenic treatment in the hyperkinetic syndrome. Lancet 1985; 1:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/77\">",
"      Egger J, Stolla A, McEwen LM. Controlled trial of hyposensitisation in children with food-induced hyperkinetic syndrome. Lancet 1992; 339:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/78\">",
"      Carter CM, Urbanowicz M, Hemsley R, et al. Effects of a few food diet in attention deficit disorder. Arch Dis Child 1993; 69:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/79\">",
"      Schmidt MH, M&ouml;cks P, Lay B, et al. Does oligoantigenic diet influence hyperactive/conduct-disordered children--a controlled trial. Eur Child Adolesc Psychiatry 1997; 6:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/80\">",
"      Pelsser LM, Frankena K, Toorman J, et al. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. Lancet 2011; 377:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/81\">",
"      Ghuman JK. Restricted elimination diet for ADHD: the INCA study. Lancet 2011; 377:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/82\">",
"      Bekaro��lu M, Aslan Y, Gedik Y, et al. Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. J Child Psychol Psychiatry 1996; 37:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/83\">",
"      Sorgi PJ, Hallowell EM, Hutchins HL, Sears B. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr J 2007; 6:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/84\">",
"      Stevens LJ, Zentall SS, Deck JL, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 1995; 62:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/85\">",
"      Raz R, Gabis L. Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review. Dev Med Child Neurol 2009; 51:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/86\">",
"      Gillies D, Sinn JKh, Lad SS, et al. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2012; 7:CD007986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/87\">",
"      Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 2011; 50:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/88\">",
"      Halterman JS, Kaczorowski JM, Aligne CA, et al. Iron deficiency and cognitive achievement among school-aged children and adolescents in the United States. Pediatrics 2001; 107:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/89\">",
"      Konofal E, Lecendreux M, Arnulf I, Mouren MC. Iron deficiency in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2004; 158:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/90\">",
"      Konofal E, Lecendreux M, Deron J, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol 2008; 38:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/91\">",
"      Millichap JG, Yee MM, Davidson SI. Serum ferritin in children with attention-deficit hyperactivity disorder. Pediatr Neurol 2006; 34:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/92\">",
"      Hollowell JG, van Assendelft OW, Gunter EW, et al. Hematological and iron-related analytes--reference data for persons aged 1 year and over: United States, 1988-94. Vital Health Stat 11 2005; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/93\">",
"      Donfrancesco R, Parisi P, Vanacore N, et al. Iron and ADHD: Time to Move Beyond Serum Ferritin Levels. J Atten Disord 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/94\">",
"      Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry 2004; 4:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/95\">",
"      Arnold LE, DiSilvestro RA. Zinc in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005; 15:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/96\">",
"      Arnold LE, Bozzolo H, Hollway J, et al. Serum zinc correlates with parent- and teacher- rated inattention in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005; 15:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/97\">",
"      Thapar A, Fowler T, Rice F, et al. Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. Am J Psychiatry 2003; 160:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/98\">",
"      Linnet KM, Dalsgaard S, Obel C, et al. Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. Am J Psychiatry 2003; 160:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/99\">",
"      Braun JM, Kahn RS, Froehlich T, et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect 2006; 114:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/100\">",
"      Milberger S, Biederman J, Faraone SV, Jones J. Further evidence of an association between maternal smoking during pregnancy and attention deficit hyperactivity disorder: findings from a high-risk sample of siblings. J Clin Child Psychol 1998; 27:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/101\">",
"      Weissman MM, Warner V, Wickramaratne PJ, Kandel DB. Maternal smoking during pregnancy and psychopathology in offspring followed to adulthood. J Am Acad Child Adolesc Psychiatry 1999; 38:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/102\">",
"      Kotimaa AJ, Moilanen I, Taanila A, et al. Maternal smoking and hyperactivity in 8-year-old children. J Am Acad Child Adolesc Psychiatry 2003; 42:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/103\">",
"      Mick E, Biederman J, Faraone SV, et al. Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J Am Acad Child Adolesc Psychiatry 2002; 41:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/104\">",
"      Froehlich TE, Lanphear BP, Auinger P, et al. Association of tobacco and lead exposures with attention-deficit/hyperactivity disorder. Pediatrics 2009; 124:e1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/105\">",
"      Lou HC. Etiology and pathogenesis of attention-deficit hyperactivity disorder (ADHD): significance of prematurity and perinatal hypoxic-haemodynamic encephalopathy. Acta Paediatr 1996; 85:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/106\">",
"      St Sauver JL, Barbaresi WJ, Katusic SK, et al. Early life risk factors for attention-deficit/hyperactivity disorder: a population-based cohort study. Mayo Clin Proc 2004; 79:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/107\">",
"      Lindstr&ouml;m K, Lindblad F, Hjern A. Preterm birth and attention-deficit/hyperactivity disorder in schoolchildren. Pediatrics 2011; 127:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/108\">",
"      Aronson M, Hagberg B, Gillberg C. Attention deficits and autistic spectrum problems in children exposed to alcohol during gestation: a follow-up study. Dev Med Child Neurol 1997; 39:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/109\">",
"      Knopik VS, Heath AC, Jacob T, et al. Maternal alcohol use disorder and offspring ADHD: disentangling genetic and environmental effects using a children-of-twins design. Psychol Med 2006; 36:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/110\">",
"      Boyd TA, Ernhart CB, Greene TH, et al. Prenatal alcohol exposure and sustained attention in the preschool years. Neurotoxicol Teratol 1991; 13:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/111\">",
"      Keenan HT, Hall GC, Marshall SW. Early head injury and attention deficit hyperactivity disorder: retrospective cohort study. BMJ 2008; 337:a1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/53/4954/abstract/112\">",
"      Zwi M, Clamp P. Injury and attention deficit hyperactivity disorder. BMJ 2008; 337:a2244.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 602 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-8377BC303A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4954=[""].join("\n");
var outline_f4_53_4954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Comorbid disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS: PRIMARY FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neuroanatomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Clinical correlation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Catecholamine metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOGENESIS: POTENTIAL ENVIRONMENTAL INFLUENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dietary influences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Food additives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Refined sugar",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Food sensitivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Essential fatty acids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Zinc deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/602\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/602|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/27/11709\" title=\"table 1\">",
"      DSM-IV-TR criteria for ADHD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32761?source=related_link\">",
"      Adult attention deficit hyperactivity disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/21/1370?source=related_link\">",
"      Clinical features and evaluation of reading difficulty in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6409?source=related_link\">",
"      Normal reading development and etiology of reading difficulty in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/32/11778?source=related_link\">",
"      Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/8/33922?source=related_link\">",
"      Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=related_link\">",
"      Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_53_4955="[ARC]Consensus sleep diary";
var content_f4_53_4955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F87134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F87134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Consensus Sleep Diary",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Questions 1 through&nbsp;10 are to be completed within one hour of getting out of bed in the morning. Questions 11 through 15 are to be completed before bed.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Camey CE, Buysse DJ, Ancoli-Israel S, et al. The Consensus Sleep Diary: Standardizing Prospective Sleep Self-Monitoring. Sleep 2012; 35:287. Copyright &copy; 2012 American Academy of Sleep Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4955=[""].join("\n");
var outline_f4_53_4955=null;
var title_f4_53_4956="Pt selection laser surgery";
var content_f4_53_4956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient selection criteria for laser refractive surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Age 18 years or older with appropriate expectations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stable refraction at least one year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myopia between -.50 and -12.00 diopters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Astigmatism &le;5.00 diopters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperopia &lt;+6.00 diopters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Absence of ocular contraindications:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Keratoconus, pellucid marginal degeneration, keratoglobus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Herpetic keratitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Progressive myopia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Corneal disease*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Glaucoma*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cataract*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Any other pre-existing pathology of the cornea or anterior segment, including scarring, lagophthalmos, severe dry eye and blepharitis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Absence of medical contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Uncontrolled vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Autoimmune disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Immunosuppressed/immunocompromised",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pregnant or nursing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        History of keloids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of use of systemic medication such as isotretinoin, amiodarone",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Determined by ophthalmologist.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4956=[""].join("\n");
var outline_f4_53_4956=null;
var title_f4_53_4957="Causes of dizziness in children and adolescents";
var content_f4_53_4957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of dizziness in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        True vertigo*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pseudovertigo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign paroxysmal positional vertigo",
"       </td>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Arrhythmia",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Benign positional vertigo of childhood",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Anemia",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholesteatoma",
"       </td>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Anxiety",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         CNS infection&bull;",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Depression",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital defects&Delta;",
"       </td>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Heat illness",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Head trauma",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Hyperventilation",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Labyrinthitis (Vestibular neuritis)",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Hypoglycemia",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mastoiditis",
"       </td>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Orthostatic hypotension",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meniere disease",
"       </td>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Poisoning or adverse effect of medication",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Middle ear trauma",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Pregnancy",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Migraine",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Presyncope",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Motion sickness",
"        </span>",
"       </td>",
"       <td>",
"        Visual disturbances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple sclerosis",
"       </td>",
"       <td rowspan=\"8\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Otitis media",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perilymph fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Poisoning or adverse effect of medication",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ramsay Hunt syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Stroke",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Tumor",
"        </span>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <span style=\"color:#ff0000\">",
"     Red",
"    </span>",
"    indicates serious or life-threatening conditions;",
"    <span style=\"color:#008000\">",
"     green",
"    </span>",
"    indicates common conditions.",
"    <br>",
"     <div class=\"footnotes\">",
"      CNS: central nervous system.",
"      <br>",
"       * True vertigo refers to dizziness with a sense of spinning.",
"       <br>",
"        <span class=\"bullet\">",
"         &bull;",
"        </span>",
"        Meningitis, encephalitis, or intracranial abscess.",
"        <br>",
"         &Delta; Eg, Mondini dysplasia, Usher syndrome, Joubert syndrome, Schiebe deformity, enlarged vestibular aqueduct syndrome.",
"        </br>",
"       </br>",
"      </br>",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4957=[""].join("\n");
var outline_f4_53_4957=null;
var title_f4_53_4958="Causes dilated cardiomyopathy";
var content_f4_53_4958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of dilated cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Ischemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Infectious diseases",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Viral Coxsackievirus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Cytomegalovirus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          HIV",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Varicella",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Hepatitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Epstein-Barr",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Echovirus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Other",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Bacterial",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Streptococci-rheumatic fever",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Typhoid fever",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Diphtheria",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Brucellosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Psitticosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rickettsial disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lyme disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Mycobacterial-fungal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Histoplasmosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Cryptococcosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Parasitic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Toxoplasmosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Trypanosomiasis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Shistosomiasis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Trichinosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Deposition diseases",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hemochromatosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amyloidosis",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Medications",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Chemotherapeutic agents",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Anthracyclines",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Cyclophosphamide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Trastuzumab",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Antiretroviral drugs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Zidovudine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Didanosine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Zalcitabine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phenothiazines",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chloroquine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Clozapine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Toxins",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ethanol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cocaine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amphetamines",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cobalt",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lead",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Mercury",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carbon monoxide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Beryllium",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Electrolyte abnormalities",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypocalcemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypophosphatemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Uremia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Nutritional deficiencies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Thiamine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Selenium",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carnitine",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Rheumatologic diseases",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Systemic lupus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Scleroderma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Giant cell arteritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Endocrinologic disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Thyroid hormone excess or deficiency",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Growth hormone excess or deficiency",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pheochromocytoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diabetes mellitus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cushing's disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Genetic with or without neuromuscular disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Duchenne's muscular dystrophy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Myotonic dystrophy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Friedreich's ataxia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          and others",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Miscellaneous",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Peripartum cardiomyopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tachycardia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sarcoidosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Familial cardiomyopathies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sleep apnea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Autoimmune myocarditis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Radiation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Calcium overload",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Oxygen free radical damage",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4958=[""].join("\n");
var outline_f4_53_4958=null;
var title_f4_53_4959="Dimensions coronary arteries for children";
var content_f4_53_4959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coronary artery dimensions for children below 18 years of age based on body surface area",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 518px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean and prediction limits for 2 and 3 SDs for size of (A) LAD, (B) proximal RCA, and (C) LMCA according to body surface area for children &lt;18 years old. LMCA z scores should not be based on dimension at orifice and immediate vicinity; enlargement of LMCA secondary to Kawasaki disease usually is associated with ectasia of LAD, LCX, or both. The dimensions of coronary arteries in children are small (in the order of a few milimeters in internal diameter). In order to minimize measurement errors, the echocardiogram should be obtained using a transducer with the highest possible frequency. The image should be zoomed before measuring coronary artery segments. Multiple measurements should be done to ensure reproducibility.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Newburger, JW, Takahashi, M, et al. Diagonsis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004: 110:2747.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_53_4959=[""].join("\n");
var outline_f4_53_4959=null;
